CHARACTERIZING THE MECHANISM OF DIFFERENTIAL
PHARMACOKINETIC DISPOSITION OF TWO STRUCTURALLY SIMILAR
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, ZIDOVUDINE AND
Didanosine

by

Sung-Hack Lee

A Dissertation submitted to the
Graduate School-New Brunswick
Rutgers, The State University of New Jersey
in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy
Graduate Program in
Pharmaceutical Sciences
written under the direction of
Patrick J. Sinko
and approved by

________________________
________________________
________________________
________________________

New Brunswick, New Jersey

[May 2008]
ABSTRACT OF THE DISSERTATION

Characterizing the Mechanism of Differential Pharmacokinetic Disposition of Two Structurally Similar Nucleoside Reverse Transcriptase Inhibitors, Zidovudine and Didanosine

By SUNG-HACK LEE

Dissertation Director:
Patrick J. Sinko

The differential contributions of efflux transporters and metabolizing enzymes to the disposition of zidovudine (azidothymidine, AZT) and didanosine (dideoxyinosine, ddI) were investigated using murine and human cells, mouse kidney slices, and mice. Cellular transport, transport in mouse kidney slices, brain uptake, and urinary excretion of AZT and ddI were investigated.

Fumitremorgin C (FTC), a breast cancer resistance protein (BCRP) specific inhibitor), increased AZT accumulation, but had little or no effect on ddI accumulation in either HEK-R482 or in J774. Involvement of BCRP was investigated by comparing results in Mock- and BCRP- transfected cells, and confirmed by repeating the studies after silencing BCRP using siRNA. MK-571, a MRP family inhibitor, blocked the efflux of AZT and ddI in murine and human cells. Silencing MRP3 and MRP4 attenuated the efflux of AZT while silencing MRP1 attenuated ddI efflux. The effect of blocking efflux transporters was found to be minor as compared to inhibition of metabolizing enzymes.
The major form of AZT deposited inside murine cells was AZT-MP, while the major form found inside human cells was AZT-TP. MK-571 abolished the efflux of AZT-MP in both murine and human cells. However, the efflux of AZT, ddI and their metabolites was not affected by FTC. Application of MK-571 also decreased the efflux of GAZT and ddI in kidney slices. The urinary excretion of AZT and ddI with MK-571 in mice was measured. MK-571 did not cause any significant changes in the urinary excretion of AZT, ddI, or their metabolites between the MK-571 untreated and treated groups.

Collectively, the results of these studies indicate that AZT and ddI are substrates of BCRP and MRPs, however since their effects are limited in in situ and in vivo situation they appear to be relatively minor players in the overall disposition of these drugs.
Dedication

I dedicate this thesis to:

My lovely wife, Ji Young Kim

My precious children, Dong-Jin Lee and Hee-Jin Lee

My mother, Gap-Nam Cho

My late father, Jong-Yeol Lee

My only brother, Jun-Hack Lee

My mother-in-law, Ok-Yeol Ju

My father-in-law, Dae-Sup Kim

My grandmother-in-law, Chin-Sun Kim

My sister-in-law, Ji-Hye Kim

My brother-in-law, Jae Moon Kim

All my friends in Korea and United States
Table of Contents

Abstract of the Dissertation.................................................................ii
Preface.................................................................................................iv
Acknowledgement..............................................................................v

I. INTRODUCTION.............................................................................. 1

II. BACKGROUND.................................................................................. 3
    A. Nucleoside Reverse Transcriptase Inhibitors as a treatment of HIV infection... 3
    B. Clinical pharmacokinetic properties of Zidovudine and Didanosine .......... 5
    C. Drug metabolism of Zidovudine and Didanosine ........................................ 9
    D. Influx and efflux transporters of Zidovudine and Didanosine .................. 14
    E. RNA interference of drug transporters .................................................. 19

III. THE CONTRIBUTION OF EFFLUX TRANSPORTERS SUCH AS BCRP
    AND MRPS ON CELLULAR EFFLUX PROFILE OF AZT AND DDI ....... 25
    A. Introduction...................................................................................... 25
    B. Materials and Methods .................................................................... 27
       1. Materials .......................................................................................... 27
       3. Electroporation-silencing of specific gene expression ......................... 30
       4. Cellular uptake and efflux ................................................................ 31
    C. Results............................................................................................... 33
       1. Expression and silencing of BCRP in human and murine cell lines......... 33
       2. Uptake and efflux of AZT and ddi in human and murine cell lines ....... 37
    D. Discussion.......................................................................................... 50
IV. THE METABOLIC PROFILES OF AZT AND DDI IN MOUSE AND HUMAN CELLS ................................................................. 52

A. Introduction .................................................................................................................................................. 52

B. Materials and Methods .......................................................................................................................... 54

1. Effect of metabolizing enzymes ........................................................................................................ 54

2. Radio-HPLC analysis of AZT and its metabolites .............................................................................. 54

3. Radio-HPLC analysis of ddi and its metabolites ................................................................................. 55

C. Results ...................................................................................................................................................... 56

1. Metabolism limits the uptake of AZT and ddi in human embryonic kidney cells and murine macrophage cells ........................................................................................................ 56

2. Effect of AZT phosphorylation on AZT efflux .................................................................................. 60

3. Effect of ddi phosphorylation on ddi efflux ......................................................................................... 65

D. Discussion .................................................................................................................................................. 67

V. THE ROLE OF DRUG EFFLUX AND METABOLISM ON THE URINARY DISPOSITION OF AZT AND DDI .......................................................... 69

A. Introduction ................................................................................................................................................ 69

B. Materials and Methods .......................................................................................................................... 71

1. Urinary excretion of AZT and ddi in mice ............................................................................................. 71

2. Measurement of intrinsic clearance .................................................................................................. 72

3. Pharmacokinetic analysis .................................................................................................................. 72

C. Results ...................................................................................................................................................... 73

1. Effect of novobiocin on oral absorption of ddi in rats ........................................................................ 73

2. Intrinsic clearance from mouse kidney slices ..................................................................................... 75
Lists of tables

Table 1. List of currently available anti-HIV drugs in US (Total 20 drugs including prodrug)........................................................................................................................ 2
Table 2. Pharmacokinetic parameters of AZT and ddI in mouse, rat, and human ............. 7
Table 3. In vitro and in vivo examples of delivery of transporter siRNA in mammals.... 20
List of illustrations

Figure 1. The HIV life cycle. Source from Bedrij et al, HIV/AIDS Industry Report (2005) ...................................................................................................................................... 3

Figure 2. Diagram of metabolism of Zidovudine (AZT) including a sequential enzymatic phosphorylation steps required for activating AZT to the triphosphate moiety. Source from Veal et al., Gen. Pharmac. (1995) ....................................................................... 8

Figure 3. Reverse-phase HPLC profiles of 3H-AZT and its metabolites. Extracellular medium of cultured hepatocytes from rats and humans was analyzed after a 24-hr incubation period with 10 μM AZT. Peaks 1, 2, 3, and 4 represent, respectively, tritiated water (THO), 3’-amino-3’-deoxythymidine (AMT), 5-O-glucuronide of AZT (GAZT), and AZT (total counts applied to column ranged from 57,000 to 62,000 dpm; scale increment: 5,000 dpm). Source from Nicolas et al., Drug Metab. Dispos. (1995) .................................................................................................................................... 11

Figure 4. Abbreviated model for ddI metabolism showing both its breakdown and its activation to the active antiviral agent ddATP. The presence of products of PNP may be inhibitory because of the unfavorable equilibrium of PNP. Source from Ray et al., Antimicrob. Agents Chemother. (2004).......................................................................................... 13

Figure 5. Basolateral and apical organic anion transporters (OATs) of the human proximal tubule. Source from Robertson et al., Pharmacol. Ther. (2006) .............................................. 16

Figure 6. A membrane topology model of BCRP. BCRP contains one nucleotide binding domain (NBD) followed by one membrane-spanning domain (MSD) with 6 predicted transmembrane α-helices. Two or 3 putative N-glycosylation sites (N418, N557, or N596) are predicted to be in the extracellular loops as indicated. Source from Mao et al., AAPS J (2005)...................................................................................................... 18

Figure 7. Effects of MDR1 siRNAs in Caco-2 cells. (A) The sequences of the synthetic siRNAs within the sites of siRNA libraries. (B) The level of MDR1 mRNA in the siRNA transfected Caco-2 cells. After transfection for 48 h, GAPDH mRNA (internal control) and MDR1 mRNA were measured by RT-PCR. (C) Accumulation study of the siRNA transfected Caco-2 cells. After transfection for 4 days, the intracellular amount of [3H]digoxin (4 nM), with or without verapamil (100 μM), was examined. Control, control siRNA; non-treated, medium only. Adapted from Pharm Res (2005) by Watanabe et al. ............................................................................................................................ 22

Figure 8. Transcellular transport study of MDR1 substrates. Time profiles for the transcellular transport across the B2-2 clone and the control cells. (A) Vincristine (435 nM). (B) Rhodamine 123 (10 μM). (C) Daunomycin (62.5 nM). The circles and the triangle represent the transcellular transport in the apical-to-basal and the basal-to-apical directions, respectively. Adapted from Pharm Res (2005) by Watanabe et al. .................................................................................................................................... 23

Figure 9. Representative (A) agarose gel from RT-PCR and (B) Western blot of bcrp level in J774.1 cell extracts ................................................................................................. 34

Figure 10. Effect of siRNA on abcg2 mRNA expression in murine macrophage cells. J774.1 and J774.2 cells were electroporated with 100 pmol of abcg2 siRNAs targeting various regions of the abcg2 gene. Electroporation without siRNA was used as control.
Twenty-four hours later, total RNA was extracted from the cells and semi-quantitative RT-PCR was performed. (A) Relative bcrp/gapdh level (%) and (B) Representative agarose gel (*: p < 0.05, n = 2) .......................................................... 35

Figure 11. Time dependency of siRNA on abcg2 mRNA expression in murine macrophage cells. J774.1 and J774.2 cells were electroporated with 100 pmol of abcg2 siRNAs targeting various regions of the abcg2 gene. Electroporation without siRNA was used as control. One or two days later, protein was extracted from the cells and Western blot was performed (*: p < 0.05, n = 2) ............................................................................. 36

Figure 12. Effect of siBCRP on TPT uptake. Cellular uptake of TPT (10 uM) into J774.1 cells after 20 min incubation with/without GG918 (1 uM), or NOV (100 uM). J774.1 cells were electroporated one day before the uptake study with 100 pmol of bcrp1 siRNAs (*: p < 0.05, n = 2) .................................................................................. 37

Figure 13. Effect of FTC, GG918, and NOV on 3H-AZT and 3H-ddI uptake. Cellular uptake of 3H-AZT and 3H-ddI (1 uM) into (A) HEK-R482 cells and (B) J774.2 cells after 30 min incubation with/without 10 uM FTC, 1 uM GG918, or 10 uM NOV (*: p < 0.05, n = 3) ................................................................................................................. 39

Figure 14. Effect of FTC on the efflux kinetics of (A) 3H-AZT and (B) 3H-ddI in HEK-Mock and HEK-R482 cells. HEK-Mock and HEK-R482 were incubated in a drug-free medium with/without FTC (5 uM) for 60 min after 90 min coincubation of 3H-AZT and 3H-ddI (1 uM) with/without FTC (n = 3).................................................................................. 41

Figure 15. Effect of siBCRP on the uptake and efflux of AZT and ddI. Cellular uptake of (A) 3H-AZT and (C) 3H-ddI after 90 min incubation and efflux kinetics of (B) 3H-AZT and (D) 3H-ddI in a drug-free medium for 60 min. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siBCRP (*:p < 0.05, n = 3) ............................................................................................................................. 43

Figure 16. Effect of bcrp1 siRNA on the efflux kinetics of AZT and ddI. Efflux kinetics of (A) 3H-AZT and (B) 3H-ddI in a drug-free medium for 60 min after 90 min incubation of drug. J774.2 cells were electroporated one day before the uptake study with 100 pmol of bcrp1 siRNA (n = 3) ......................................................................................................................... 44

Figure 17. Effect of siMRP1 ~ 4 on the uptake of AZT. Cellular uptake of 3H-AZT after 90 min incubation. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siMRP1 ~ 4 (*: p < 0.05, n = 3)............................................................................. 45

Figure 18. Effect of siMRP1 ~ 4 on the uptake of ddI. Cellular uptake of 3H-ddI after 90 min incubation. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siMRP1 ~ 4 (*: p < 0.05, n = 3)............................................................................. 46

Figure 19. Release of ddI from HEK-R482. Plot of efflux rate at 30 sec from HEK-R482 cell versus estimated intracellular concentration of ddI over the range of 1 ~ 400 uM (n = 3) ............................................................................................................................. 47

Figure 20. Release of AZT from HEK-R482. (A) Plot of efflux rate at 30 sec from HEK-R482 cells versus estimated intracellular concentration of AZT over the range of 10 ~ 4000 uM. (B) Relationship of the intracellular and the initial extracellular concentration of AZT (n = 3) ......................................................................................................................... 48

Figure 21. Effect of MK-571 on the efflux kinetics of 3H-AZT in (A) HEK-R482 and (B) J774.2 cells. HEK-R482 and J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (n = 3) ......................................................................................................................... 49
Figure 22. Effect of MK-571 on the efflux kinetics of 3H-ddI in (A) HEK-R482 and (B) J774.2 cells. HEK-R482 and J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-ddI (1 uM) with/without MK-571 (n = 3) ................................................................. 50

Figure 23. Effect of ATP depletion on (A) cellular uptake and (B) relative efflux of AZT in HEK-R482 cells. ATP depleted cells were maintained in the presence of ATP synthesis inhibitors during the uptake phase. For efflux, cells were either incubated in a substrate-free medium without ATP inhibitors (ATP regen.) or in the continuing presence of the ATP inhibitors (ATP deplet.) (*: p < 0.05, n = 3) ....................... 57

Figure 24. Effect of ATP depletion on (A) cellular uptake and (B) relative efflux of AZT in J774.1 cells. ATP depleted cells were maintained in the presence of ATP synthesis inhibitors during the uptake phase. For efflux, cells were either incubated in a substrate-free medium without ATP inhibitors (ATP regen.) or in the continuing presence of the ATP inhibitors (ATP deplet.) (*: p < 0.05, n = 3) .............. 58

Figure 25. Effect of thymidine and probenecid on 3H-AZT accumulation. Cellular accumulation of 3H-AZT (1 uM) in (A) HEK-R482 cells and (B) J774.2 cells after 90 min incubation with/without 20 uM thymidine or 1 mM probenecid (*: p < 0.05, n = 3) ........................................................................................................ 60

Figure 26. Effect of MK-571 on 3H-AZT and its metabolites uptake. Cellular uptake of 3H-AZT (1 uM) and its metabolites into J774.2 cells after 30 min incubation with/without 100 uM MK-571 (*: p < 0.05, n = 3) ................................................................................. 61

Figure 27. Effect of MK-571 on the efflux kinetics of 3H-AZT and AZT-MP in J774.2 cells. J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (*: p < 0.05, n = 3) ........................................................................................................ 62

Figure 28. Effect of MK-571 on 3H-AZT and its metabolites uptake. Cellular uptake of 3H-AZT (1 uM) and its metabolites into HEK-R482 cells after 30 min incubation with/without 100 uM MK-571 (*: p < 0.05, n = 3) ................................................................................. 63

Figure 29. Effect of MK-571 on the efflux kinetics of 3H-AZT and AZT-MP in HEK-R482 cells. HEK-R482 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (*: p < 0.05, n = 3) ........................................................................................................ 64

Figure 30. Typical HPLC radiochromatogram of an efflux media sample incubated with 3H-AZT in HEK-R482 cells ....................................................................................... 65

Figure 31. Effect of MK-571 on 3H-ddI and its metabolites uptake. Cellular uptake of 3H-ddI (1 uM) and its metabolites into HEK-R482 cells after 30 min incubation with/without 100 uM MK-571 (*: p < 0.05, n = 3) ................................................................................. 66

Figure 32. Typical HPLC radiochromatogram of an uptake media sample incubated with 3H-ddI in HEK-R482 cells ....................................................................................... 67

Figure 33. Mass spectra of ddI at the full scan mode (m/z range = 150 ~ 600). ............ 73

Figure 34. Chromatogram of ddI and internal standard ddC from the standard sample (2 ug/ml). Multiple reaction monitoring (MRM) mode at four channels: m/z of parent/daughter ion = 495/259 and 259/159 for ddI, 445/234 and 423/212 for ddC, in control serum when methanol was used for deproteinization .............................................................. 74

Figure 35. Mean arterial plasma concentration-time profile of didanosine (ddI) after oral administration at a dose of 20 mg/kg in Sprague-Dawley rats. ddI was administered
with/without 50 mg/kg novobiocin (NOV). Each points represents means +/- SD (n = 3)................................................................................................................................. 75

Figure 36. Effect of Fumitremorgin C (FTC) on the efflux kinetics of 3H-AZT and GAZT in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without FTC (10 μM) for 60 min after 90 min coincubation of 3H-AZT (1 μM) with/without FTC (*: p < 0.05, n = 3)................................................................................................................................. 76

Figure 37. Effect of MK-571 on (A) the efflux profile and (B) the relative efflux profile of 3H-AZT and GAZT in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without MK-571 (100 μM) for 60 min after 90 min coincubation of 3H-AZT (1 μM) with/without MK-571 (*: p < 0.05, n = 3)............. 77

Figure 38. Effect of Fumitremorgin C (FTC) on the efflux kinetics of 3H-ddI and ddA-MP in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without FTC (10 μM) for 60 min after 90 min coincubation of 3H-ddI (1 μM) with/without FTC (*: p < 0.05, n = 3)........................................................................ 78

Figure 39. Effect of MK-571 on (A) the efflux profile and (B) the relative efflux profile of 3H-ddI and ddA-MP in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without MK-571 (100 μM) for 60 min after 90 min coincubation of 3H-ddI (1 μM) with/without MK-571 (*: p < 0.05, n = 3)................... 79

Figure 40. Effects of MK-571 on the urinary excretion of AZT in mice. AZT (10 mg/kg) with trace amount of 3H-AZT was injected through the tail vein with or without MK-571 (50 mg/kg). The excreted amount of AZT and GAZT over a period of 24 hr in a urine sample to the percent of the injected amount were determined (p < 0.05, n = 3).................................................................................................................................... 80

Figure 41. Effects of MK-571 on the urinary excretion of ddI in mice. ddI (10 mg/kg) with trace amount of 3H-ddI was injected through the tail vein with or without MK-571 (50 mg/kg). The excreted amount of ddI and ddAT-MP over a period of 24 hr in a urine sample to the percent of the injected amount were determined (p < 0.05, n = 3)..... 81

Figure 42. Structure of the carotid arteries around the neck of FVB mouse. ................... 86

Figure 43. Effect of in vivo injection of naked siRNA of bcrp1. One day after IV injection (50 ug siRNA), protein was extracted respectively from liver and kidney and Western blot were performed. Each points represents means+SD (*: p < 0.05, n = 3) ............ 90

Figure 44. Apparent brain distributional volumes of 3H-ddI (1 μM) in the absence and presence of MK-571 (100 μM), which was included in the perfusates. Brain vascular volume was measured using 14C-sucrose. The mice were perfused for 60 sec and perfusion flow rate was 2.1 ml/min (n = 4)........................................................................................................... 91

Figure 45. Apparent brain distributional volumes of 14C-SQV (1 μM) in the absence and presence of MK-571 (100 μM), which was included in the perfusates. Brain vascular volume was measured using 3H-mannitol. The mice were perfused for 60 sec and perfusion flow rate was 2.1 ml/min (n = 4)........................................................................................................... 92

Figure 46. Apparent brain distributional volumes of ddI versus concentration of ddI, which was included in the perfusates. Brain vascular volume was measured using 14C-sucrose. The mice were perfused for 60 s. Perfusion flow rate was 2.1 ml/min (*: p < 0.05, n = 4)........................................................................................................... 93
I. INTRODUCTION

Although zidovudine (AZT) and didanosine (ddI) are the oldest FDA approved drugs for the treatment of Human Immunodeficiency Virus (HIV) infection, their market is still among the largest of anti-HIV drugs (~$2 billion in 2004 including combination formulations, Table 1), and they are clearly prescribed more often than other antiviral drugs. Since AZT and ddI were launched in 1987 and 1991, respectively, their ADME properties have been extensively studied. AZT is dominantly metabolized to glucuronides (Cretton et al., 1990) and ddI is hydrolyzed to hypoxanthine (Stoeckler et al., 1980). But, there are many other metabolizing enzymes such as phosphorylating kinases or 5-nucleotidase and transporters such as ATP-binding cassette (ABC) transporters and organic anion transporters (OATs) that are involved with the disposition of AZT and ddI. Furthermore, the reported mechanisms of metabolism and/or efflux are not sufficiently understood and cannot explain their pharmacokinetic properties. The major factors affecting the pharmacokinetic behavior of AZT and ddI are described in the following sections and this information will be used to develop effective dosing regimens.
Table 1. List of currently available anti-HIV drugs in US (Total 20 drugs including prodrug)

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Abbreviation</th>
<th>Experimental Code</th>
<th>Sales (2004)</th>
<th>Change (vs. 03)</th>
<th>Launch</th>
<th>Pharmaceutical Company</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Videx®</td>
<td>Didanosine: buffered</td>
<td>ddI</td>
<td>BMY-40900</td>
<td>↓</td>
<td>↓</td>
<td>1991</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Videx® EC</td>
<td>Didanosine: delayed-release</td>
<td>ddI</td>
<td></td>
<td>$274M</td>
<td>3%</td>
<td>2000</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Zerit®</td>
<td>Stavudine</td>
<td>d4T</td>
<td>BMY-27857</td>
<td>$272M</td>
<td>-23%</td>
<td>1994</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Emtriva™</td>
<td>Emtricitabine*</td>
<td>FTC</td>
<td></td>
<td>$58M</td>
<td>---</td>
<td>2003</td>
<td>Gilead</td>
</tr>
<tr>
<td>Retrovir®</td>
<td>Zidovudine</td>
<td>AZT or ZDV</td>
<td></td>
<td>$80M</td>
<td>4%</td>
<td>1987</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Epivir®</td>
<td>Lamivudine</td>
<td>3TC</td>
<td></td>
<td>$549M</td>
<td>4%</td>
<td>1995</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Combid®</td>
<td>Zidovudine + Lamivudine</td>
<td>AZT + 3TC</td>
<td></td>
<td>$1067M</td>
<td>4%</td>
<td>1997</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Ziagen®</td>
<td>Abacavir</td>
<td>ABC</td>
<td>1592U89</td>
<td>$290M</td>
<td>0%</td>
<td>1998</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Trizivir®</td>
<td>Abacavir + Zidovudine + Lamivudine</td>
<td>ABC + AZT + 3TC</td>
<td></td>
<td>$602M</td>
<td>-8%</td>
<td>2000</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Hivid®</td>
<td>Zalcitabine</td>
<td>ddC</td>
<td></td>
<td>---</td>
<td>---</td>
<td>1992</td>
<td>Roche</td>
</tr>
<tr>
<td><strong>Nucleotide Reverse Transcriptase Inhibitors (NiRTI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viread®</td>
<td>Tenofovir DF</td>
<td>TDF or Bsi(POC) PMPA</td>
<td></td>
<td>$783M</td>
<td>---</td>
<td>2003</td>
<td>Gilead</td>
</tr>
<tr>
<td><strong>Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viramune®</td>
<td>Nevirapine</td>
<td>NVP</td>
<td>BI-RG-587</td>
<td>$409M</td>
<td>-8%</td>
<td>1996</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Sustiva®</td>
<td>Efavirenz</td>
<td>EFV</td>
<td>DMP-266</td>
<td>$621M</td>
<td>14%</td>
<td>1998</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Rescriptor®</td>
<td>Delavirdine</td>
<td>DLV</td>
<td>U-90152S/T</td>
<td>---</td>
<td>---</td>
<td>1997</td>
<td>Pfizer (Agouron)</td>
</tr>
<tr>
<td><strong>Protease Inhibitors (PIs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norvir®</td>
<td>Ritonavir</td>
<td>RTV</td>
<td>ABT-538</td>
<td>---</td>
<td>---</td>
<td>1996</td>
<td>Abbott</td>
</tr>
<tr>
<td>Kaletra®</td>
<td>Lopinavir + Ritonavir</td>
<td>LPV</td>
<td>ABT-378/r</td>
<td>$896M</td>
<td>19%</td>
<td>2000</td>
<td>Abbott</td>
</tr>
<tr>
<td>Reyataz™</td>
<td>Atazanavir*</td>
<td>ATZ</td>
<td>BMS-232632</td>
<td>$414M</td>
<td>---</td>
<td>2003</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Agenerase®</td>
<td>Amprenavir</td>
<td>APV</td>
<td>141W94 or VX-478</td>
<td>↓</td>
<td>↓</td>
<td>1999</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Lexiva®</td>
<td>Fosamprenavir*</td>
<td>FPV</td>
<td>GW-433908 or VX-175</td>
<td>$121M</td>
<td>80%</td>
<td>2003</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Crixivan®</td>
<td>Indinavir</td>
<td>IDV</td>
<td>MK-639</td>
<td>$255M</td>
<td>-10%</td>
<td>1996</td>
<td>Merck</td>
</tr>
<tr>
<td>Viracept®</td>
<td>Nelfinavir</td>
<td>NFV</td>
<td>AG-1343</td>
<td>~ $200M</td>
<td>-23%</td>
<td>1997</td>
<td>Pfizer (Agouron)</td>
</tr>
<tr>
<td>Invirase®</td>
<td>Saquinavir (Hard Gel Cap)</td>
<td>SQV (HGC)</td>
<td>Ro-31-8959</td>
<td>↓</td>
<td>↓</td>
<td>1995</td>
<td>Roche</td>
</tr>
<tr>
<td>Fortovase®</td>
<td>Saquinavir (Soft Gel Cap)</td>
<td>SQV (SGC)</td>
<td>~ $110M</td>
<td>14%</td>
<td>1997</td>
<td>Roche</td>
<td></td>
</tr>
<tr>
<td><strong>Entry Inhibitors (including Fusion Inhibitors)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fuzen®</td>
<td>Enfuvirtide*</td>
<td>ENF</td>
<td>T-20</td>
<td>$135M</td>
<td>27%</td>
<td>2003</td>
<td>Roche</td>
</tr>
</tbody>
</table>

*Fosamprenavir (2003): prodrug of Amprenavir (Agenerase)
*Atazanavir (2003): 7th FDA-approved HIV protease inhibitor
*Emtricitabine (2003): 7th FDA-approved nucleoside reverse transcriptase inhibitor (NRTI)
*Enfuvirtide (2003): new class of fusion inhibitors (SC injection)
II. BACKGROUND

A. Nucleoside Reverse Transcriptase Inhibitors as a Treatment of HIV Infection

The HIV is a retrovirus that causes a slow and progressive weakening of the immune system, which results in acquired immunodeficiency syndrome (AIDS).

Figure 1. The HIV life cycle. Source from Bedrij et al, HIV/AIDS Industry Report (2005)
The virus inserts its own RNA into host cell DNA, preventing natural cell processes and commencing production of HIV in the host organism. Viral RNA is converted to viral DNA by reverse transcriptase and this DNA is then inserted into the host organism’s genome. From one patient infected with HIV, over 10 billion copies of the virus are produced everyday making it easy for HIV to spread quickly through the body. Although HIV infects various types of cells, major target of HIV is T4-lymphocytes (also known as “T-helper” cells). The T4-cell has multiple CD4 receptors, or proteins, and co-receptors such as CCR5 and CXCR-4 on its surface. HIV selectively destroys CD4 expressing cells and, when the number of CD4 cells drops to around 200 cells/µL of blood because of HIV infection, the body's immune system deteriorates (Eyster et al., 1989). When the number of CD4 cells drops below 200 cells/µL of blood, a person with HIV infection is officially said to have AIDS. Reverse Transcriptase Inhibitors block proliferation of HIV by inhibiting reverse transcriptase and the conversion of HIV RNA into viral DNA. Two types of reverse transcriptase inhibitors are introduced for HIV treatment: the “nucleoside” analogue reverse transcriptase inhibitors (NRTIs) and the “non-nucleoside” reverse transcriptase inhibitors (NNRTIs). NRTIs mimic the building blocks used by reverse transcriptase to replicate the HIV genetic material thus disrupting the reverse transcription process. NNRTIs bind directly to reverse transcriptase, and physically prevent the reverse transcriptase from adding new nucleotides to the viral DNA chains.

NRTIs, the main class of reverse transcriptase inhibitors, are converted into their active triphosphate form within cells by phosphorylation. They then resemble natural nucleosides found in human cells and they are able to disrupt the construction of proviral DNA during reverse transcription. In other words, instead of taking up a nucleoside from
the deposited supply in the cell, reverse transcriptase uses a faulty building block (i.e., the nucleoside analogue drug) instead. These “faulty” building blocks do not form the necessary chemical bonds with natural nucleosides and the DNA chain is unable to remain intact. The incomplete chain is unable to correct itself and the process of viral replication is thereby interrupted. The major problem of these drugs is that they may be utilized by healthy reproducing cells thus preventing regular production of healthy new cells as well. The likelihood of nucleoside analogues halting reproduction of healthy cells is not very good, since reverse transcriptase has a much higher affinity for nucleoside analogs rather than DNA polymerase (Zakharova et al., 1995). Also, human cells are able to fix problems with their DNA production process during cell reproduction phase. NRTIs are mainly used in combination therapies also known as “cocktails”. When two NRTIs are used with another anti-HIV drug (usually an NNRTI or a protease inhibitor) for a total of 3 drugs, the combination has been found to block HIV replication quite well. Seven NRTIs are currently available: abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, and zidovudine. Several drugs in the NRTI class are also currently used as a component of antiretroviral combination therapy. NRTIs are expected to remain as the most robust class of HIV drugs in terms of overall sales (Chrystyna Bedrij, 2005).

B. Clinical pharmacokinetic properties of Zidovudine and Didanosine

**Zidovudine** Pharmacokinetic parameters of AZT and ddI are listed in Table 2. Oral absorption of AZT is good with a reported bioavailability of between 60% and 70% (Beach, 1998). AZT is subject to hepatic first-pass metabolism (Yarchoan et al., 1986; Blum et al., 1988; Morse et al., 1993). Oral absorption is affected by food consumption, in
particular high-fat meals, resulting in delayed absorption (Unadkat et al., 1990). AZT achieves cerebrospinal fluid (CSF) levels that are approximately 75% of plasma concentration by AUC (Rolinski et al., 1997). Thirty-five percent of AZT is protein bound (Collins and Unadkat, 1989). AZT undergoes metabolism to its glucuronide, the major plasma and urinary metabolism (Singlas et al., 1989). The major organs in AZT glucuronidation are the liver, possibly the kidney and the intestinal mucosa. AZT plasma levels are increased by coadministration of other drugs that are substrates and/or inhibitors of glucuronidation (Sim et al., 1991). Fourteen percent of parent AZT and 74% of the glucuronide of the oral dose have been recovered from the urine in healthy volunteers.
Table 2. Pharmacokinetic parameters of AZT and ddl in mouse, rat, and human

<table>
<thead>
<tr>
<th></th>
<th>AZT</th>
<th>ddl</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mouse</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( t_{1/2} ) (min)</td>
<td>66</td>
<td>16</td>
</tr>
<tr>
<td>( \text{CL} ) (ml/min/kg)</td>
<td>23</td>
<td>39</td>
</tr>
<tr>
<td>( \text{CLr} ) (ml/min/kg)</td>
<td>16</td>
<td>---</td>
</tr>
<tr>
<td>Bioavailability (%)</td>
<td>82~92</td>
<td>15</td>
</tr>
<tr>
<td>Urine recovery (IV total, %)</td>
<td>86 (87% parent)</td>
<td>---</td>
</tr>
<tr>
<td>Kidney T/P ratio (Total)</td>
<td>0.7~53 (inc.)</td>
<td>---</td>
</tr>
<tr>
<td>Kidney T/P ratio (unch)</td>
<td>1.97~2.74 (flat)</td>
<td>---</td>
</tr>
<tr>
<td><strong>Rat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \text{CL}_{\text{int,in vitro}} )</td>
<td>14.3</td>
<td>---</td>
</tr>
<tr>
<td>( \text{CL}_{\text{int,in vivo}} )</td>
<td>18.4</td>
<td>---</td>
</tr>
<tr>
<td>( t_{1/2} ) (min)</td>
<td>21~26</td>
<td>29~33</td>
</tr>
<tr>
<td>( \text{CL} ) (ml/min/kg)</td>
<td>28</td>
<td>66</td>
</tr>
<tr>
<td>( \text{CLr} ) (ml/min/kg)</td>
<td>14~16</td>
<td>14~19</td>
</tr>
<tr>
<td>Urine recovery (IV unch, %)</td>
<td>50~57</td>
<td>21~28</td>
</tr>
<tr>
<td>Urine recovery (IV total, %)</td>
<td>---</td>
<td>51 (95% parent)</td>
</tr>
<tr>
<td>Urine recovery (PO total, %)</td>
<td>78</td>
<td>12</td>
</tr>
<tr>
<td>Kidney T/P ratio (Total)</td>
<td>8</td>
<td>2.3</td>
</tr>
<tr>
<td>Bioavailability (%)</td>
<td>---</td>
<td>8~11</td>
</tr>
<tr>
<td><strong>Human</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \text{CL}_{\text{int,in vitro}} )</td>
<td>9.87</td>
<td>---</td>
</tr>
<tr>
<td>( \text{CL}_{\text{int,in vivo}} )</td>
<td>28.4</td>
<td>---</td>
</tr>
<tr>
<td>( t_{1/2} ) (min)</td>
<td>66</td>
<td>84</td>
</tr>
<tr>
<td>( \text{CL} ) (ml/min/kg)</td>
<td>19</td>
<td>11</td>
</tr>
<tr>
<td>( \text{CLr} ) (ml/min/kg)</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Plasma protein binding (%)</td>
<td>35</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>Bioavailability (%)</td>
<td>60~70</td>
<td>25~43</td>
</tr>
<tr>
<td>Urine recovery (IV unch, %)</td>
<td>---</td>
<td>55</td>
</tr>
<tr>
<td>Urine recovery (PO unch, %)</td>
<td>14</td>
<td>18</td>
</tr>
<tr>
<td>Urine recovery (PO total, %)</td>
<td>90</td>
<td>---</td>
</tr>
</tbody>
</table>
The renal excretion of the drug is mediated by both glomerular filtration and active tubular secretion (Klecker et al., 1987; Blum et al., 1988). AZT is converted intracellularly to the triphosphate form like other nucleoside analogues (Figure 2). This conversion is accomplished via cellular thymidine kinase (Furman et al., 1986). The triphosphate of AZT (AZT-TP) acts as an inhibitor of HIV RT and as a chain terminator. In the phosphorylation of AZT, the rate-limiting step is the conversion of the parent drug to its monophosphate form (Ho and Hitchcock, 1989). This conversion causes the monophosphate and the diphosphate to accumulate within the cell.

Figure 2. Diagram of metabolism of Zidovudine (AZT) including a sequential enzymatic phosphorylation steps required for activating AZT to the triphosphate moiety. Source from Veal et al., Gen. Pharmac. (1995)
**Didanosine** Oral bioavailability of ddI ranges from 43% to 25%, depending on whether an antacid or buffer tablet is used (Beach, 1998). Didanosine is very unstable in the stomach because of its’ acidic condition. Commercially available formulations of ddI include a buffer solution and tablet. ddI is also given with an antacid. The latter seems to achieve the best bioavailability (Hartman et al., 1991). In addition, it is recommended that ddI be taken in the fasting state because of the high acid condition associated with eating (Hartman et al., 1990; Knupp et al., 1991). Penetration of ddI into the CSF is low, showing a CSF-to-plasma ratio of 0.21 in adults after 60 min infusion (Hartman et al., 1990). Protein binding of ddI is less than 5% (Perry and Balfour, 1996). Renal excretion is the major elimination route for ddI (Beach, 1998). It has been shown to undergo both glomerular filtration and active tubular secretion. Urinary recovery was 55% after single intravenous dose and 20% after single oral dose. Intracellularly, ddI is converted to its monophosphate (ddI-MP) via the cytosolic 5’-nucleotidase, which uses inosine monophosphate as the phosphate donor (Johnson and Fridland, 1989). Monophosphate of ddI is then converted to dideoxy adenosine monophosphate (ddA-MP) by the actions of adenylosuccinate synthetase and adenylosuccinate lyase. The ddA-MP is further phosphorylated to the level of triphosphate, which is an inhibitor of HIV RT and acts as a terminator of the viral DNA chain (Ahluwalia et al., 1987; Johnson et al., 1988).

### C. Drug metabolism of Zidovudine and Didanosine

**Glucuronidation of AZT** AZT undergoes significant hepatic metabolism via glucuronidation. The metabolite profiles of AZT in rat and human indicated that two metabolites are identified as 5’-O-glucuronide of AZT (GAZT) and
3’-amino-3’-deoxythymidine (AMT), and GAZT is the major metabolite observed in extracellular as well as in intracellular medium in cultured hepatocytes (Cretton et al., 1990). However, marked quantitative differences are observed between rats and humans. 24 hr after incubation of AZT, the majority of radioactivity was recovered as unchanged drug in rat (86% of total extracellular radioactivity). In contrast, higher proportions of metabolites (~70% of the total extracellular radioactivity) were recovered in culture media of human hepatocytes (Figure 3).
Figure 3. Reverse-phase HPLC profiles of 3H-AZT and its metabolites. Extracellular medium of cultured hepatocytes from rats and humans was analyzed after a 24-hr incubation period with 10 μM AZT. Peaks 1, 2, 3, and 4 represent, respectively, tritiated water (THO), 3’-amino-3’-deoxythymidine (AMT), 5-O-glucuronide of AZT (GAZT), and AZT (total counts applied to column ranged from 57,000 to 62,000 dpm; scale increment: 5,000 dpm). Source from Nicolas et al., Drug Metab. Dispos. (1995)

Unchanged drug represented 88% of the radioactivity excreted in urine after 3H-AZT administration in rats, whereas GAZT represented 52% in human urine samples. This glucuronide was the main metabolite of AZT in both rats and humans. However, some differences are apparent between in vivo and in vitro metabolic profiles. Besides the formation of GAZT, two other metabolites were formed in humans in vivo (Stagg et al.,...
1992), and in rat hepatocyte suspensions (Cretton and Sommadossi, 1991; Cretton et al., 1991). They were identified as 3'-amino-3'-deoxothyridine (AMT) and its glucuronide derivative (GAMT).

**Phosphorolysis of ddI** Purine nucleoside phosphorylase (PNP) is suspected to be the mechanism of ddI clearance. It is reported that ddI is a good substrate for PNP in enzymatic assays (Stoeckler et al., 1980) and is rapidly degraded in cultured cells, producing hypoxanthine and phosphorylated sugar moiety (Ahluwalia et al., 1987; Weibel et al., 1994). Radiolabeled hypoxanthine appears in dog studies after treatment with 14C-labeled ddI (Kaul et al., 1993) and ddI has a short half-life of 38 min in clinical studies (Hartman et al., 1990). PNP is an omnipresent enzyme, which functions in the purine nucleoside rescue pathway. In physiological situation, the function of PNP is the phosphorolysis of inosine and guanosine nucleosides. Abbreviated models for the activation of ddI to the active antiviral and the metabolism of ddI are proposed (Ray et al., 2004)(Figure 4).
Figure 4. Abbreviated model for ddI metabolism showing both its breakdown and its activation to the active antiviral agent ddATP. The presence of products of PNP may be inhibitory because of the unfavorable equilibrium of PNP. Source from Ray et al., Antimicrob. Agents Chemother. (2004)
The highest levels of PNP activity are found in erythrocytes, granulocytes, peripheral blood lymphocytes, and kidney cells. The large proportion of blood volume occupied by erythrocytes and high PNP levels in erythrocytes make the erythrocyte a likely disposition site of ddI.

**Phosphorylation of AZT and ddI**  As described in previous section, the nucleoside analogues are taken up by target cells, phosphorylated to the 5’-triphosphate by cellular enzymes and incorporated into target DNA. Drug effect is determined not only by dose and the rate of elimination, but by the rate and extent of intracellular phosphorylation. This explains, in part, why plasma concentrations of nucleoside analogues have proved disappointing in predicting efficacy or toxicity. In the case of AZT phosphorylation, the process appears to be saturable and therefore increases in plasma concentration do not cause proportional increases in total phosphate concentrations. The main intracellular phosphorylated metabolite is AZT monophosphate (AZT-MP) which is explained by the fact that conversion of AZT-MP to AZT diphosphate (AZT-DP) by the enzyme thymidylate kinase is the rate determining step for the AZT intracellular pathway. AZT shares the same intracellular phosphorylating enzymes with stavudine and lamivudine. Therefore, coadministration of these drugs could result in an interaction at the phosphorylation level. Conversely, didanosine is activated by a unique pathway converting it to dideoxyadenosine triphosphate (ddA-TP) instead of dideoxyadenosine triphosphate (ddI-TP).

**D. Influx and efflux transporters of Zidovudine and Didanosine**
**Organic Anion Transporters**  Influx of AZT and ddI is facilitated by numerous transporters. The uptake of AZT and ddI is mediated by the sodium-dependent organic anion transporter (OAT) system, which includes sodium-ketoglutarate cotransport via the Na\(^+\)/dicarboxylate cotransporter and \(\alpha\)-ketoglutarate/organic anion exchange via the OAT1 (Takeda et al., 2002). During the past decade, several OATs have been cloned from various tissues and species. OAT1 plays a primary role in the tubular active secretion of endogenous and xenobiotic organic anions. Uptake by OAT1 is a tertiary active process, dependent on a dicarboxylate-gradient established by co-transport of Na\(^+\) and dicarboxylate, a secondary active process, which is, in turn, dependent upon the Na\(^+\)-gradient established by the primary active Na\(^+\)/K\(^+\) ATPase (Figure 5).
Nucleoside transporters  Nucleoside transporters (SLC28, SLC29) can also transport NRTIs including AZT and ddI (Anderson et al., 1999; Jennings et al., 2001; Baldwin et al., 2004). There are two families of nucleoside transporters, equilibrative (ENTs, SLC29) and concentrative (CNTs, SLC28). Most cells have low-affinity ENT systems. The human SLC29 family contains four hENTs. The ENT1 and ENT2 systems are driven by the concentration gradient of nucleosides, and can mediate bi-directional nucleoside flux. A study has indicated that ddI, but not AZT, crosses the guinea-pig blood brain barrier by means of the nucleoside transporter (Gibbs et al., 2003). hENT2 transports both ddI and AZT whereas hENT1 only transports ddI (Yao et al., 2001). High affinity CNTs mediate
the flux of nucleosides coupled to the movement of sodium down its electrochemical
gradient. Three have been molecularly identified (CNT1~3) and are expressed by the liver,
intestine, kidney, and choroids plexus (Gray et al., 2004). CNT1 is implicated in the renal
handling and intestinal absorption of AZT. CNT2 is expressed at the blood-brain barrier
(BBB) and can transport ddI. hCNT3 transports both AZT and ddI. Considerable species
differences exist in the tissue distribution of CNT3 in humans, mice and rats. In epithelia,
CNTs are located in the apical membrane, whilst ENTs are detected in the basolateral
membrane, suggesting a coordinating role of CNTs and ENTs in transepithelial
nucleosides and NRTIs (Gray et al., 2004). The direction of these transporters is
absorptive and the function of these transporters is not covered in the current experimental
design.

**Breast Cancer Resistance Protein**  BCRP, a recently discovered transporter, is reported
to be a transporter of AZT and ddI (Wang et al., 2004). BCRP belongs to the subfamily G
of the large ABC transporter superfamily. BCRP is designated as ABCG2, the second
member of subfamily G. At present, 4 members in the subfamily G such as ABCG1,
ABCG2, ABCG5, and ABCG8 have been identified in human. Unlike P-gp and MRP1,
which are composed of 2 repeated halves, ABCG transporters are half transporters that has
a single nucleotide binding domain (NBD) and a single membrane-spanning domain
(MSD) (Ross, 2000)(Figure 6).
Figure 6. A membrane topology model of BCRP. BCRP contains one nucleotide binding domain (NBD) followed by one membrane-spanning domain (MSD) with 6 predicted transmembrane α-helices. Two or 3 putative N-glycosylation sites (N418, N557, or N596) are predicted to be in the extracellular loops as indicated. Source from Mao et al., AAPS J (2005)

Increasing evidence suggests that ABCG proteins may function as either homodimers or heterodimers (Graf et al., 2003; Xu et al., 2004). Another unique feature of ABCG transporters is the domain arrangement in which the NBD is followed by the MSD, whereas P-gp or MRP1 has an opposite configuration, that is, the MSD precedes the NBD. Such a unique domain configuration is not observed in other human ABC transporters than subfamily G and implies that the transport mechanisms of ABCG transporters may be different from those of other ABC proteins. It has been reported that BCRP transports several NRTIs such as AZT and ddI, but is not an efficient transporter of protease inhibitors (Allen and Schinkel, 2002; Huisman et al., 2002; Wang et al., 2004). Like P-gp,
BCRP is expressed on the apical side of polarized epithelium such as that in the gut, liver, and kidney (Schinkel and Jonker, 2003; Borst et al., 2004), and on the luminal side of the brain capillary endothelium (Maliepaard et al., 2001). This allows removal of AZT and ddI from the body by transporting them into urine, bile, or the intestine.

**Multidrug resistance protein 4**  Mrp4 expression is highest in the kidney in mice (Maher et al., 2005) and rats (Chen and Klaassen, 2004), and is localized to the apical membrane of proximal tubules in human kidney (van Aubel et al., 2002). Veal et al. reported that AZT-MP was secreted from many different cell types, although the efficiency of secretion varied among cells (Frick et al., 1988; Veal and Back, 1995). Secretion of AZT-MP is not due to leakage or cytotoxicity and is specific for AZT-MP, as AZT diphosphate or AZT triphosphate was not found in the extracellular medium (Frick et al., 1988). Subsequent studies by Fridland et al. confirmed that AZT-MP was effluxed (Fridland et al., 1990). It is notable that AZT-MP efflux appeared inducible as long term incubations with AZT caused an increased rate of AZT-MP efflux. Because AZT cytotoxicity is related to the uptake of AZT-MP, one could speculate that this active transport from cells is a cytoprotective mechanism (Hall et al., 1994; Tornevik et al., 1995). The ability of MRP4 to transport AZT-MP and the localization of MRP4 in kidney suggest that it may play an important role in renal clearance of AZT.

**E. RNA interference of drug transporters**

The successful launch of siRNA as a laboratory tool and therapeutic agent has been cited in more than 1000 publications to date and has led to an application to drug transporters. ATP-binding cassette (ABC) transporters were one of the earlier target candidates of
siRNA since they play a major role in cancer multidrug resistance. Here, we introduce the *in vitro* and *in vivo* application of siRNA silencing of drug transporters (Table 3).

### Table 3. In vitro and in vivo examples of delivery of transporter siRNA in mammals

<table>
<thead>
<tr>
<th>Target</th>
<th>Type of siRNA</th>
<th>Delivery of siRNA</th>
<th>Selected Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In vitro</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp</td>
<td>Naked siRNA</td>
<td>Lipid based reagent</td>
<td>(Wu et al., 2003)</td>
</tr>
<tr>
<td>Vector shRNA</td>
<td>Stable expression</td>
<td>(Xu et al., 2004)</td>
<td></td>
</tr>
<tr>
<td>Vector siRNA</td>
<td>Lipid based reagent</td>
<td>(Zhang et al., 2005)</td>
<td></td>
</tr>
<tr>
<td>Vector shRNA</td>
<td>Recombinant adeno-associated virus</td>
<td>(Xu et al., 2005)</td>
<td></td>
</tr>
<tr>
<td>Mrp1</td>
<td>Naked siRNA</td>
<td>Lipid based reagent</td>
<td>(Lee et al., 2004)</td>
</tr>
<tr>
<td>Mrp2,3</td>
<td>Naked siRNA</td>
<td>Lipid based reagent</td>
<td>(Tian et al., 2004)</td>
</tr>
<tr>
<td>Bcrp</td>
<td>siRNA + T7 promoter</td>
<td>Lipid based reagent</td>
<td>(Ee et al., 2004)</td>
</tr>
<tr>
<td>Vector siRNA</td>
<td>Adenovirus</td>
<td>(Li et al., 2005b)</td>
<td></td>
</tr>
<tr>
<td>Naked siRNA</td>
<td>Lipid based reagent</td>
<td>(Hori et al., 2005)</td>
<td></td>
</tr>
<tr>
<td><strong>In vivo</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp</td>
<td>Modified siRNA</td>
<td>Simple IV injection</td>
<td>(Su et al., 2005)</td>
</tr>
<tr>
<td>Vector shRNA</td>
<td>Hydrodynamic IV injection</td>
<td>(Pichler et al., 2005)</td>
<td></td>
</tr>
<tr>
<td>Naked siRNA</td>
<td>Hydrodynamic IV injection</td>
<td>(Matsui et al., 2005)</td>
<td></td>
</tr>
</tbody>
</table>

*In vitro* applications

The rate limiting step in siRNA-mediated silencing is the delivery of these small molecules into the desired cells. Even though siRNA is gene specific, targeted delivery to cells of interest is important since many transporters are expressed in numerous cell types. This is not a major concern in the *in vitro* setting because cells are studied in isolation. However, *in vivo* use of siRNA becomes a “drug” delivery problem that is quite daunting and similar in scope to gene and antisense oligonucleotide delivery. The delivery of transporter-targeted siRNAs is achieved by electroporation or transfection of naked siRNA or by gene transfer using a vector. Among the 70 articles published to date that relate to siRNA and transporters, most of them have targeted P-gp as it relates to drug disposition or cancer chemoresistance. For functional transport analysis, a P-gp knock-down Caco-2 cell line
has been developed (Watanabe et al., 2005). All five MDR1 siRNAs (A1 ~ B2) based on the guideline for designing effective sequence specifically ablated the MDR1 mRNA and the uptake of digoxin, p-gp substrate was significantly increased in the siRNA-transfected cells (Figure 7).

The transcellular transport of typical p-gp substrates was evaluated using two hairpin siRNAs expressing A2 and B2 sequences (A2-2 and B2-2)(Figure 8). Two MDR1 hairpin siRNAs lowered the basal-to-apical directional flux of the substrates from 2 ~ 6 times higher levels to the equivalent levels to the opposite directional fluxes.
Figure 7. Effects of MDR1 siRNAs in Caco-2 cells. (A) The sequences of the synthetic siRNAs within the sites of siRNA libraries. (B) The level of MDR1 mRNA in the siRNA transfected Caco-2 cells. After transfection for 48 h, GAPDH mRNA (internal control) and MDR1 mRNA were measured by RT-PCR. (C) Accumulation study of the siRNA transfected Caco-2 cells. After transfection for 4 days, the intracellular amount of [3H]digoxin (4 nM), with or without verapamil (100 uM), was examined. Control, control siRNA; non-treated, medium only. Adapted from Pharm Res (2005) by Watanabe et al.
Figure 8. Transcellular transport study of MDR1 substrates. Time profiles for the transcellular transport across the B2-2 clone and the control cells. (A) Vincristine (435 nM). (B) Rhodamine 123 (10 μM). (C) Daunomycin (62.5 nM). The circles and the triangle represent the transcellular transport in the apical-to-basal and the basal-to-apical directions, respectively. Adapted from Pharm Res (2005) by Watanabe et al.
In general, preparing a stable transfectant is a time consuming process, making transient transfection of naked siRNA and siRNA-plasmid a more favorable option. More recently, BCRP has become a new target for researchers performing transient transfection with siRNA (Hori et al., 2005; Li et al., 2005) due to its importance in brain uptake, oral absorption, and multidrug resistance.

**In vivo applications**

In contrast to the great interest and progress of *in vitro* siRNA transfection, there are few reports of *in vivo* use of siRNA. This, of course, is related to the central issue of siRNA delivery. There are two key siRNA properties that make its *in vivo* delivery difficult. First, siRNA is rapidly degraded by both extracellular and intracellular nucleases. Chemical modification increases its stability, also potentially increasing the overall cellular uptake of siRNA as well. A proprietary stabilized MDR1 siRNA (siSTABLE, Dharmacon) was recently shown to ablate the expression of P-gp in MCF-7 cancers inoculated into SCID mice (Su et al., 2005). The second factor that challenges the *in vivo* delivery of siRNA is poor intrinsic membrane permeability. This is attributed to physicochemical properties such as the large polar surface area and molecular size of siRNA molecules. A method that has been used in the preclinical setting with some success involves the hydrodynamic intravenous injection of naked siRNA or hairpin siRNA. This method has enhanced siRNA delivery (Lewis et al., 2002; McCaffrey et al., 2002). The technique of hydrodynamic injection involves injecting a large volume (> 2 ml / mouse) of siRNA solution over short period of time (< 10 sec). Mouse mdr1a/1b and human MDR1 gene has been successfully knocked down by using the hydrodynamic injection of the corresponding siRNA and/or hairpin siRNA (Matsui et al., 2005; Pichler et al., 2005).
Selection of a target gene specific siRNA is critical for proper *in vivo* transfection. Delivery is still a problem especially in clinical applications since current delivery methods such as hydrodynamic iv infusion and electroporation cannot be safely applied to human subjects.

### III. THE CONTRIBUTION OF EFFLUX TRANSPORTERS SUCH AS BCRP AND MRPS ON CELLULAR EFFLUX PROFILE OF AZT AND DDI

#### A. Introduction

In most cases drug-resistant HIV strains resulting from genetic mutations discovered in patients treated with antiviral therapy (Berger et al., 1998) explain the mechanisms of drug resistance. However, some patients show signs of drug resistance even in the absence of drug-resistant viral strains (Plotkin et al., 1985; Groschel et al., 1997) suggesting alternative mechanisms of resistance. The alteration of the systemic disposition of antiviral drugs and the presence of pharmacokinetic sanctuary sites limiting the accessibility to antiviral agents have been considered as alternative or additional mechanisms of resistance. Urinary excretion is one of the major dispositional pathways for AZT and ddI and more than two thirds of AZT total clearance is explained by renal clearance in mice (Doshi et al., 1989). In the clinical application of AZT, 14% and 76% of an oral dose is recovered through urinary excretion as parent and its’ metabolites, respectively. Urinary recoveries of unchanged ddI after intravenous and oral administration are 55% and 18%, respectively. The renal clearances of these drugs are 2 ~ 3 times higher than the glomerular filtration rate (GFR) suggesting active tubular secretion
of both drugs. Generally, influx of anionic drugs into kidney tubular cells is predominantly mediated by OAT transporters (Enomoto et al., 2002). This is consistent with the observations that an organic anion reduces the renal clearance of AZT \textit{in vivo} (Takeda et al., 2002). However, the plasma to tissue ratio in the kidney is around two fold, supporting the existence of efflux transporters in the brush border membrane. Renal ABC transporters play an important role as drug and metabolite efflux transporters. For all NRTIs including AZT and ddI, it is important to consider intracellular drug exposures as NRTI triphosphate concentrations because these are the moieties responsible for antiviral activity and toxicity (Anderson et al., 2004).

Clinical pharmacokinetic drug-drug interactions give an indirect indication of the metabolism or efflux of drugs. One example is the interaction of AZT with probenecid. Coadministration of probenecid increased plasma half-life and maximum plasma concentration of AZT significantly, and it also doubled the AUC of AZT (de Miranda et al., 1989; Kornhauser et al., 1989). Probenecid is known to inhibit both AZT metabolism and the renal elimination of GAZT (Hedaya et al., 1990).

While P-glycoprotein (p-gp) has been proposed as a major efflux transporter for AZT and ddI, there is evidence that AZT and ddI are not p-gp substrates (Leung and Bendayan, 1999). Wang et al. found that the cytotoxicity of AZT and ddI was reduced in drug-resistant MT-4/DOX500 (BCRP-overexpressing cells) compared to the parental MT-4 cells, suggesting that AZT and ddI are BCRP substrates (Wang et al., 2004). Gene and protein expression levels of BCRP are measured in our cellular and animal system using RT-PCR and Western blot. The efflux function of BCRP was investigated using cellular uptake and efflux studies. Induction of BCRP is regulated by aryl hydrocarbon
receptor (AhR, (Ebert et al., 2005)) and pregnane X receptor (PXR, (Anapolsky et al., 2006)). The cellular model of bcrp1-induction was developed to magnify the role of bcrp1 in the efflux of AZT and ddI. Members of the MRP family are also interesting ABC transporters in the study of AZT and ddI. Two members of the family, MRP4 and MRP5, appear to transport AZT (Schuetz et al., 1999; Wijnholds et al., 2000), while BCRP is responsible for the efflux of both AZT and ddI. The role of MRP4 in NRTI drug resistance was discovered when CEM cells exposed to AZT developed a drug resistance in absence of drug resistant virus (Schuetz et al., 1999). They found that AZT-MP was pumped out of cells in an energy (ATP) dependent manner caused by increased expression of MRP4. Our current work suggested that ddI or its metabolite might also be a substrate of the MRP family. Wijnholds et al. has shown that MRP5 also appears to be an NRTI pump (Wijnholds et al., 2000). Wang et al. found that the cytotoxicity of AZT and ddI was reduced in drug-resistant MT-4/DOX500 (BCRP-overexpressing cells) compared to the parental MT-4 cells, suggesting that AZT and ddI are BCRP substrates (Wang et al., 2003). The objective of this investigation is to identify the role of each efflux transporter on the cellular efflux profile of AZT and ddI. To elucidate the role of each transporter on the cellular efflux of AZT and ddI in mice, intracellular and extracellular concentrations of AZT and ddI were monitored in mouse macrophage 774.1 cells and human embryonic kidney HEK-R482 cells.

B. Materials and Methods

1. Materials
AZT and ddI were generously supplied by GlaxoSmithKline (London, UK) and Bristol-Myers Squibb (New York, NY), respectively. SuperScript First-Strand Synthesis System for RT-PCR, Platinum® Taq DNA Polymerase, Trizol, Benchmark Protein Ladder, Opti-MEM I Reduced Serum Medium, and DMEM were purchased from Invitrogen (Carlsbad, CA). Ready Gel Precast Gels and Laemmli sample buffer were obtained from Bio-Rad (Hercules, CA). T-PER, BCA protein assay kit, SuperSignal West Femto Maximum Sensitivity Substrate, and Restore Western Blot Stripping Buffer were obtained from Pierce (Rockford, IL). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific (Fair Lawn, NJ) and used as received. Primary and secondary antibodies were obtained from Kamiya Biomedical (Seattle, WA) or Santa Cruz Biotechnology (Santa Cruz, CA).

2. Measurement of genetic and protein expression level

**RT-PCR**  Total RNA was extracted from cells and animal tissues using TRIZOL reagent (Invitrogen). Total amount of RNA was calculated by measuring the OD260 of 100x diluted RNA solution. First-strand reaction and PCR amplification were performed according to the manufacturer’s protocol with modification. The solution containing RNA sample (1 ~ 2 µg), random hexamers (50 ng/µl), and dNTP mixture (10 mM) was incubated at 65°C for 5 min, and was mixed into a reaction tube containing 10x RT buffer, MgCl₂ (25 mM), DTT (0.1 M), and RNaseOUT. Fifty units of SuperScript II RT (Invitrogen) were added per 19 µl, and the first-strand mixture was incubated at 25°C for 10 min, 42°C for 50 min, 70°C for 15 min. To amplify a specific gene from the sample, oligonucleotide primers were designed using PrimerQuest (Integrated DNA technologies,
Coralville, IA). Amplification reactions of first strand DNA were performed with 10x PCR buffer, MgCl₂ (50 mM), Taq DNA polymerase, dNTP mixture (10 mM), and primers mixture with the following temperature protocol: 94°C for 3 min to stabilize the sample, 30 cycles (94°C for 30 sec, 60°C for 30 sec, 72°C for 1 min), 72°C for 10 min. Electrophoresis was performed by the procedure of Meyers et al. (Meyers et al., 1976) on agarose gels (1%). DNA migrates toward the anode in TAE buffer at 100 V for 1 hr. After electrophoresis, DNA bands were detected by UV light. Sizes of PCR products were determined by comparing the migration of the sample in gels to that of a standard DNA ladder (Invitrogen).

**WESTERN BLOTTING** Cells and tissues were lysed using cell lysis buffer (0.1 M Tris-HCl, 5% Triton X-100, 1.5 M NaCl, 10% SDS, and 0.1 M EDTA) with protease inhibitors (Sigma). Lysates of cells and tissues were centrifuged for 15 min at 14,000 g at 4°C. The supernatants were transferred to a fresh tube and diluted with sample buffer (x2 volume) containing 5% mercaptoethanol. Samples (50 µg of protein) were separated under denaturating conditions on a Ready Gel (10% Tris-HCl) precast gel cassette (Biorad), using TG running buffers supplemented with 0.1% sodium dodecyl sulfate (1 hr at 4°C at 150 V). Separated proteins were transferred on a PVDF membrane (Novel) for 30 min at 100 V, in a TG transfer buffer with 20% methanol. The membranes were blocked in 5% nonfat milk-0.1% Tween 20 for at least 1 hr and then incubated for at least 2 hr with gentle shaking and at room temperature with Anti-BCRP primary antibody (Kamiya) after x5,000 dilution in the blocking buffer. The membranes were then exposed to the secondary antibody (anti-rat HRP-conjugated IgG, Santa Cruz). Reactive bands were
detected by chemiluminescence using a SuperSignal kit (Pierce). Molecular weights were estimated by comigration with a Benchmark protein ladder (Invitrogen). Positive identification of the BCRP band was made by analyzing in parallel lysates from HEK-R482 cells, BCRP-overexpressing cell.

3. Electroporation-silencing of specific gene expression

Predesigned siRNAs (siBCRP and siMRP1~4) were purchased from Dharmacon (Lafayette, CO). For cell types proving to be recalcitrant to lipofection-based protocols, electroporation can be a valuable alternative. Electroporation involved applying an electric field pulse to induce the formation of micro-sized pores in the cell’s plasma membrane, which then allow the siRNA to cross the membrane. Under specific pulse conditions, the pores resealed quickly and the electroporated cells recovered and resumed growth. A significant advantage of electroporation is that this method is not dependent on cell division, and RNAi-induced mRNA reduction can be detected just a few hours after delivery.

While most of electroporation protocols were developed for delivering plasmid DNA to cell nuclei, siRNAs need to be delivered only into the cytoplasm. Therefore, milder electroporation conditions can be used to minimize cell mortality while ensuring high efficiency of siRNA delivery. Human embryonic kidney HEK-R482 cells and murine macrophage J774.2 cell lines were used. For induction of bcrp1, J774.2 cells were treated with oltipraz and 2-acetylaminofluorene for 2~5 days in 6-well plate. The specific protocol for siBCRP transfection was optimized and is detailed below:
The cells were washed with 10 ml PBS (Phosphate Buffer Saline, pH 7.4) and harvested with a scraper in 10 ml DMEM. The cells were transferred to a centrifuge tube and spun at 1,200 rpm for 2.5 min to pellet the cell. The cells were resuspended in Opti-MEM I (Invitrogen) at a density of 2 x 10^6 cells/ml. In an electroporation cuvette (4 mm gap), 0.5 ml of the cell suspension was combined with 5 µl of siRNA (final concentration = 200 nM, amount = 1.2 µg), and then the cells were electroporated with ECM830 Electroporator using four 1 ms pulses with a pulse interval of 400 ms.

<table>
<thead>
<tr>
<th>Electroporation Settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voltage: 500 V (LV mode)</td>
</tr>
<tr>
<td>P. Length: 1 ms</td>
</tr>
<tr>
<td># Pulses: 4</td>
</tr>
</tbody>
</table>

After electroporation, the cells were allowed to recover at 37°C for 10 min and then they were suspended in 2 ml of pre-warmed growth media. The cells were then plated in 6-well plates and incubated in MEM or DMEM supplemented with 10% fetal bovine serum in 5% CO₂ for 24 ~ 72 hr to activate the RNAi pathway.

4. **Cellular uptake and efflux**

All experiments were performed with HEK-R482, bcrp-transfected human embryonic kidney cells and J774.1 and J774.2, mouse macrophage cells, grown as monolayers in MEM or DMEM supplemented with 10% fetal bovine serum in 5% CO₂. Cultures were initiated at a density of ca. 5 x 10^4 cells per cm² and used after 2 ~ 3 days of culture upon reaching confluence. For critical determinations, the amount of protein was assessed at the
end of the experiments by measuring absorbance at 570 nm with a BCA protein assay kit (Pierce).

**Uptake and efflux assays.** After 20 min preincubation with HBSS buffer, cells were treated with 3H-AZT or 3H-ddI with/without transporter inhibitors in 0.5 ml HBSS. At 30 ~ 120 min after incubation, cell monolayers were washed three times with ice-cold phosphate buffer and lysed overnight with 200 µl of 1 N NaOH. The amount of cell-associated AZT or ddI was either analyzed by β-scintillation counting or High Performance Liquid Chromatography (HPLC) analysis as described in the next section. For the efflux study, cells were incubated for 60 ~ 120 min with inhibitors and washed three times with ice-cold PBS. Drug-free media with/without inhibitors were added to each well, and extracellular drug concentrations were measured at 3, 10, 30, and 60 min. Intracellular uptake in efflux study was calculated by summing up the amounts at each time point and the remaining amount in the cell at the end of the experiments. Intracellular uptake in uptake study was calculated by measuring the amount in the cell at specified time point. The cell content of AZT was then expressed by either reference to the total cell protein content or an absolute amount (pmol) per cellular volume. All assays were performed with 24 well plates in triplicates.

**Statistical analyses and curve fittings.** All the statistical analyses and curve fittings were performed using Graph Pad Prism software (Graph Pad software, San Diego, CA). Data is presented as mean ± SD. Dunnett’s multiple comparison test after ANOVA was used to compare the statistical significance of differences between experimental groups and statistical significance was determined at the level of $P=0.05$. 


C. Results

1. Expression and silencing of BCRP in human and murine cell lines

hBCRP-transfected human embryonic kidney cells (HEK-R482) were used as an in vitro model human cell system. We have also used naturally bcrp-expressing mouse macrophage cells (J774) as a model in vitro murine cell system. The gene expression level of bcrp and mrps was measured by RT-PCR and protein level of bcrp was determined using Western blot analysis (Figure 9). RNA interference (RNAi) is a sequence-specific gene silencing method using small interfering RNA (siRNA). In our in vitro cellular system, RNAi allows us to evaluate the role of specific transporters in the influx and efflux of AZT and ddI. The silencing of BCRP was accomplished by transfecting synthetic siRNA (21 base pairs) using an electroporation method. Three different siRNA duplexes were synthesized by Ambion, Dhharmacon (mixture of four different sequences), and Qiagen and the silencing potency of each siRNA was compared in J774 cells (Figure 10). The time dependency of the reduction in expression level of bcrp in J774.1 and J774.2 cells was monitored at day 1 and day 2 after siBCRP transfection. J774 cells were electroporated with 100 pmol of abcg2 siRNAs. Total protein was extracted from the cells and Western blot analysis was performed. The untreated and electroporated treated groups without siRNA were used as controls (Figure 11). Function of the expressed bcrp was verified by monitoring the relative intracellular uptake of topotecan, a known bcrp substrate, in J774.1 cells. J774.1 cells were electroporated with 100 pmol of abcg2 siRNAs. One day later, relative uptake of topotecan was measured 20 min after incubation of J774.1 and J774.2 cells with 10 µM topotecan alone or with topotecan plus 100 µM novobiocin (NOV) or 1 µM GF120918 (GG918)(Figure 12).
Figure 9. Representative (A) agarose gel from RT-PCR and (B) Western blot of bcrp level in J774.1 cell extracts.
**Figure 10. Effect of siRNA on abcg2 mRNA expression in murine macrophage cells.** J774.1 and J774.2 cells were electroporated with 100 pmol of abcg2 siRNAs targeting various regions of the abcg2 gene. Electroporation without siRNA was used as control. Twenty-four hours later, total RNA was extracted from the cells and semi-quantitative RT-PCR was performed. (A) Relative bcrp/gapdh level (%) and (B) Representative agarose gel (*: p < 0.05, n = 2)
Figure 11. Time dependency of siRNA on abcg2 mRNA expression in murine macrophage cells. J774.1 and J774.2 cells were electroporated with 100 pmol of abcg2 siRNAs targeting various regions of the abcg2 gene. Electroporation without siRNA was used as control. One or two days later, protein was extracted from the cells and Western blot was performed (*: p < 0.05, n = 2)
Figure 12. Effect of siBCRP on TPT uptake. Cellular uptake of TPT (10 uM) into J774.1 cells after 20 min incubation with/without GG918 (1 uM), or NOV (100 uM). J774.1 cells were electroporated one day before the uptake study with 100 pmol of bcrp1 siRNAs (*: p < 0.05, n = 3)

2. **Uptake and efflux of AZT and ddI in human and murine cell lines**

AZT and ddI were reported to be BCRP substrates (Wang et al., 2004). We verified and investigated the involvement of BCRP in the efflux of AZT and ddI using an established *in vitro* cell model. Chemical inhibitors and siRNA silencing of BCRP were used to suppress BCRP activity.

**Effect of BCRP inhibitors in HEK-R482 and J774.2 cells.**

The influence of known BCRP inhibitors such as fumitremorgin C (FTC), GF-120918 (GG918), and novobiocin (NOV) on the cellular uptake of AZT and ddI in HEK-R482 and
J774.2 cells were compared in Figure 13. The results demonstrate a significant increase in AZT uptake due to FTC coincubation (from $13.5 \pm 0.8$ to $24.5 \pm 1.8$ pmol/ mg protein in HEK-R482 and from $1.66 \pm 0.25$ to $2.91 \pm 0.56$ pmol/ mg protein in J774.2). Uptake of ddI increased by the addition of FTC (from $0.99 \pm 0.05$ to $1.45 \pm 0.03$ pmol/ mg protein) and, to a lesser extent, by GG918 (1.31 $\pm$ 0.07 pmol/ mg protein) in HEK-R482, whereas J774.2 cells were insensitive to all of the applied BCRP inhibitors including FTC. Currently there is not sufficient evidence to suggest why ddI uptake is not enhanced in J774.2 cells in the presence of BCRP inhibitors. We only suspect that there is a species difference in substrate specificity between human and murine BCRP. This phenomenon is very similar to our previous experience with two anticancer agents, topotecan (TPT) and SN-38. Even though both TPT and SN-38 were well known human BCRP substrates, only TPT uptake was sensitive to GG918 (1 $\mu$M) and NOV (100 $\mu$M) in our experiments (data not shown). This suggests that ddI is a BCRP substrate only in humans.
Figure 13. Effect of FTC, GG918, and NOV on 3H-AZT and 3H-ddI uptake. Cellular uptake of 3H-AZT and 3H-ddI (1 uM) into (A) HEK-R482 cells and (B) J774.2 cells after 30 min incubation with/without 10 uM FTC, 1 uM GG918, or 10 uM NOV (*: p < 0.05, n = 3)
Effect of FTC in hBCRP over-expressed cells

The effect of FTC on the uptake of AZT and ddI could be attributed to several mechanisms. For example, FTC might alter the activities of other ABC transporters, or phase I, phase II, or phosphorylating enzymes. HEK-R482 cells are stably transfected human embryonic kidney cells (HEK-293) using PC DNA 3.1 vector (Invitrogen) containing full-length wild-type BCRP whereas HEK-Mock cell is transfected with the control PC DNA 3.1 vector (Morisaki et al., 2005). The comparison between HEK-Mock and HEK-R482 should confirm the role of BCRP in the transport of the two NRTIs (Figure 14). AZT efflux in HEK-Mock was not affected by the addition of FTC, but the efflux rate of AZT in HEK-R482 was faster than in HEK-Mock \( k = 0.016 \pm 0.001 \text{ vs. } 0.007 \pm 0.001 \text{ min}^{-1}, r^2 \geq 0.999 \) and the addition of FTC eliminates the difference, making the efflux profile in HEK-R482 close to the profile in HEK-Mock \( k = 0.011 \pm 0.001 \text{ vs. } 0.007 \pm 0.001 \text{ min}^{-1}, r^2 \geq 0.999 \). This trend became more clear for ddI efflux in HEK cells \( k = 0.012 \pm 0.003 \text{ min}^{-1} \text{ for Mock control, } 0.010 \pm 0.003 \text{ min}^{-1} \text{ for Mock w/ FTC, } 0.036 \pm 0.003 \text{ min}^{-1} \text{ for R482 control, and } 0.012 \pm 0.002 \text{ min}^{-1} \text{ for R482 w/ FTC, } r^2 \geq 0.99 \).
Figure 14. Effect of FTC on the efflux kinetics of (A) 3H-AZT and (B) 3H-ddI in HEK-Mock and HEK-R482 cells. HEK-Mock and HEK-R482 were incubated in a drug-free medium with/without FTC (5 uM) for 60 min after 90 min coincubation of 3H-AZT and 3H-ddI (1 uM) with/without FTC (n = 3)

Effect of siBCRP and siMRPs

The effect of BCRP silencing siRNA was tested in human HEK-R482 cells (Figure 15) and in murine J774.2 cells (Figure 16). The results demonstrated an increase in AZT and ddI uptake in HEK-R482 by silencing BCRP (from 2.06 ± 0.32 to 5.21 ± 0.48 pmol AZT/ well and from 0.15 ± 0.05 to 0.22 ± 0.02 pmol ddI/ well). J774.2 cells were insensitive to bcrp1 silencing attempts in both uptake and efflux of AZT and ddI. ddI results were consistent with our previous results of bcrp1 inhibition by FTC, GG918, and NOV, while AZT results were somewhat unexpected because previous results showed that AZT accumulation increased in the presence of FTC. Considering high specificity of siBCRP mediated silencing, increased uptake of AZT by FTC coincubation observed in Figure 14 might be caused by off-target inhibition of FTC. In HEK-R482, the efflux rate of AZT was reduced
by applying BCRP silencing as compared to the control group ($k = 0.099 \pm 0.005$ vs. $0.075 \pm 0.008 \text{ min}^{-1}$, $r^2 \geq 0.99$). Similar results were observed with ddI in HEK-R482. Further experiments are needed to resolve this substrate specificity issue. Based on the results presented in the previous section, Bcrp-mediated efflux alone is not sufficient to explain the differences between the intracellular uptake and efflux of AZT and ddI. We used a series of conditions to demonstrate the role of metabolism and transporters other than bcrp in human and murine cells; depletion of ATP, coincubation with thymidine kinase inhibitors, and coincubation with MK-571, an MRP inhibitor. The effect of siRNAs silencing MRP1~4 were tested in human HEK-R482 cells (Figure 17, Figure 18). The data demonstrated an increase in AZT uptake by silencing MRP3 and MRP4 (from $0.22 \pm 0.01$ to $0.65 \pm 0.02$ and $0.47 \pm 0.04$ pmol AZT/ well, respectively) and an increase in ddI uptake by silencing MRP1 (from $0.031 \pm 0.002$ to $0.038 \pm 0.004$ pmol ddI/ well).
Figure 15. Effect of siBCRP on the uptake and efflux of AZT and ddl. Cellular uptake of (A) 3H-AZT and (C) 3H-ddI after 90 min incubation and efflux kinetics of (B) 3H-AZT and (D) 3H-ddI in a drug-free medium for 60 min. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siBCRP (*: p < 0.05, n = 3)
Figure 16. Effect of bcrp1 siRNA on the efflux kinetics of AZT and ddI. Efflux kinetics of (A) 3H-AZT and (B) 3H-ddI in a drug-free medium for 60 min after 90 min incubation of drug. J774.2 cells were electroporated one day before the uptake study with 100 pmol of bcrp1 siRNA (n = 3)
Figure 17. Effect of siMRP1 ~ 4 on the uptake of AZT. Cellular uptake of 3H-AZT after 90 min incubation. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siMRP1 ~ 4 (*: p < 0.05, n = 3)
Figure 18. Effect of siMRP1 ~ 4 on the uptake of ddI. Cellular uptake of 3H-ddI after 90 min incubation. HEK-R482 cells were electroporated one day before the uptake study with 100 pmol of siMRP1 ~ 4 (*: p < 0.05, n = 3)

Concentration dependency in efflux of AZT and ddI

The concentration dependence of ddI efflux in HEK-R482 cells was evaluated over the range of 1 ~ 400 µM intracellular concentrations of ddI (Figure 19). The initial efflux rate of the ddI from HEK-R482 cells was calculated from the efflux at 30 sec, which was derived from the linear portion of the efflux – time plot (data not shown). The initial rate of efflux was then plotted against the concentration of the substrate in the cell. The substrate concentration - efflux rate profile was fit to a linear model instead of the nonlinear Michaelis-Menten model since transporter-mediated portion of ddI efflux is negligible. At
the highest concentration of ddI, the velocity of the efflux was proportional to the intracellular concentration of ddI without any saturation. The concentration dependency of AZT efflux in HEK-R482 cells was also evaluated over the intracellular concentration range of 10 ~ 4,000 \( \mu M \) (Figure 20). The efflux rate per unit AZT concentration increases, which is caused by the saturation of the intracellular concentration of AZT as shown in Figure 20B. This phenomenon strongly suggests two possibilities: that either an uptake transporter or metabolizing enzyme became saturated.

Figure 19. Release of ddI from HEK-R482. Plot of efflux rate at 30 sec from HEK-R482 cell versus estimated intracellular concentration of ddI over the range of 1 ~ 400 \( \mu M \) (n = 3)
Effect of MK-571 in HEK-R482 and J774.2 cells

Since the transporters involved with AZT, ddI, and their metabolites are quite diverse, the delineation of each factor is also quite challenging. MRP4 is reported to be an efflux transporter of AZT-MP (Sampath et al., 2002). The efflux of AZT from HEK-R482 and J774.2 cells was examined (Figure 21). The accumulation of AZT after 90 min uptake in HEK-R482 was 27.2 vs. 30.9 pmol/well in the control group and in the MK-571-added group. The relative efflux of AZT was delayed in HEK-R482 cells incubated with MK-571 during AZT uptake and efflux (Figure 21A), while the relative efflux of AZT with MK-571 was the same as the control in J774.2 cells (Figure 21B). The accumulation of AZT after 90 min uptake in J774.2 was 3.0 vs. 6.0 pmole in control and MK-571-added group. The efflux processes of ddI in HEK-R482 and J774.2 macrophages were also examined (Figure 22). MK-571 doubled the 90 min uptake of ddI in HEK-R482 (control vs. MK-571 treated; 0.60 vs. 1.11 pmol/well) whereas no effect was observed in a 90 min uptake study of ddI.
with MK-571 in J774.2 (control vs. MK-571 treated; 1.13 vs. 0.86 pmol/well). The relative efflux of ddI with MK-571 in HEK-R482 and J774.2 were slower than in the control group (Figure 22).

Figure 21. Effect of MK-571 on the efflux kinetics of 3H-AZT in (A) HEK-R482 and (B) J774.2 cells. HEK-R482 and J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (n = 3)
Figure 22. Effect of MK-571 on the efflux kinetics of 3H-ddI in (A) HEK-R482 and (B) J774.2 cells. HEK-R482 and J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-ddI (1 uM) with/without MK-571 (n = 3)

D. Discussion.

It is essential to dose NRTIs correctly in order to avoid low drug concentrations in target tissues and the subsequent development of resistance, including cross-resistance to other drugs in the class. There are significant differences among the NRTIs with respect to dispositional properties. One of the factors determining the excretion rate of each NRTI is that many NRTIs are substrates for ATP-dependent efflux transporters. Efflux transporters alter the systemic disposition of NRTIs and limit the accessibility of these antiviral agents to pharmacokinetic sanctuary sites. The current experiments address two issues: 1) the study of BCRP and MRPs expression and silencing and 2) the study of uptake and efflux of AZT and ddI in human and murine cell lines. The expression of BCRP has been demonstrated at both the mRNA and protein levels. The expression of bcrp mRNA in J774
cells was confirmed by semi-quantitative RT-PCR. This finding was extended to the protein level. The signal generated with bcrp antibody on Western blots roughly correlates to mRNA level. We established the transfection method of naked siRNA using an electroporation method in this study. The selectivity was checked by measuring the expression level of unrelated GAPDH mRNA. The functional decrease of BCRP was also confirmed in this study.

We demonstrated that AZT uptake into HEK-R482 and J774.2 cells was sensitive to FTC but not to other BCRP inhibitors such as GG918 and NOV (Figure 13). An increase in inhibitor concentration had no effect on AZT uptake (data not shown). The efflux of AZT decreased significantly in the presence of FTC, but the relative difference of efflux rate constant between the control and the FTC-added group was less than 50% ($k = 0.016 \pm 0.001$ vs. $0.011 \pm 0.001$ min$^{-1}$, $r^2 \geq 0.999$)(Figure 14). Further investigation of the behavior of AZT and each metabolite using radio-HPLC is discussed in the next chapter. These two inhibitors showed clear inhibition of TPT, another well known BCRP substrate. The reason for this phenomenon is not clear, and there are two possibilities: 1) increased uptake of AZT was not mediated by blocking BCRP and 2) the mechanism of BCRP inhibition by these inhibitors did not affect the transport of AZT. The first possibility can be applied to the results in murine J774.2 cells, even though nonspecific inhibition of other efflux transporters by FTC has not been reported to date. siRNA silencing of murine bcrp1 did not decrease efflux of AZT and ddI in murine J774.2 cells (Figure 16), while siRNA silencing of human BCRP significantly increased uptake of AZT and ddI and decreased efflux of both drugs (Figure 15). Neither bcrp1 nor mrps play a significant role in efflux of AZT in the mouse. Contrary to the murine results, both BCRP and MRPs alter the uptake
and efflux profile of AZT significantly in human cells. This species difference in substrate specificity of efflux transporter is a rare and interesting discovery. The effect of bcrp1 or BCRP on the efflux of ddi is minimal. Another interesting finding is that the different MRP subfamily is responsible for the efflux of AZT and ddi. Unlike AZT, whose efflux was delayed by siMRP3 and siMRP4, the efflux of ddi was delayed only by siMRP1 (Figure 18). But, the extent of MRP1 inhibition does not explain the difference in the efflux profile by MK-571. The major inhibition effect of MK-571 treatment in Figure 18 might be caused by inhibition of transporters other than MRP1 ~ 4.

IV. THE METABOLIC PROFILES OF AZT AND DDI IN MOUSE AND HUMAN CELLS

A. Introduction

Understanding the metabolic profile (i.e., such as the rate of metabolism and the molecular structure of produced metabolites) of a drug is critical in determining a safe dosing regimen. Until now, reports on the metabolism of AZT and ddi have only focused on inter-species differences in hepatic metabolism (Cretton et al., 1990; Pan-Zhou et al., 1997; Collins, 2001). Although the majority of AZT and ddi metabolism occurs in the liver in humans, the effect of renal metabolism can not be ignored particularly in the case of drug-drug interactions. Generally speaking, significant inter-species differences in drug metabolism make interpretation of preclinical and non-clinical results and extrapolation from animals to clinical results difficult. Since there is no single model or method that can extrapolate drug metabolism from animals to humans, extensive preclinical and nonclinical pharmacokinetics and drug metabolism studies are required in laboratory animals prior to
clinical studies. AZT is a well known example of profound species differences in hepatic drug metabolism, since it was shown that most of dosed AZT was found to be glucuronidated in clinical pharmacokinetic and drug metabolism studies (Blum et al., 1988) even though in vivo animal studies suggested that metabolism of AZT would be minimal (Chow et al., 1997).

The metabolism of AZT and ddI are not only involved with classical phase I and II metabolizing enzymes but also with PNP and phosphorylating enzymes such as thymidine kinase and 5’-nucleotidase (5’-NT). AZT itself is not active, but it needs to be converted to its phosphorylated anabolites intracellularly by a series of intracellular kinases in order to exert cytotoxic or antiviral activities. Involvement of multiple metabolizing pathways is important because one of the clinical limitations of AZT is rapid clearance with a one hour plasma half-life that requiring a frequent dosing schedule. The intracellular metabolism of AZT has been extensively examined in in vitro cell lines and in human PBMCs (Furman et al., 1986; Balzarini et al., 1988; Dhawan et al., 1990; Szebeni et al., 1991).

In this section we investigate the role of thymidine kinase in AZT metabolism. We also monitored the metabolic profiles of AZT and ddI in two kinds of cultured cells, to assess the species differences in drug metabolism. This is important since different levels of enzyme activities are observed in different species from different organs and that can cause inconsistent drug distribution in various organs (Matheny et al., 2001; Ding and Kaminsky, 2003). Completely different patterns of intracellular accumulation of AZT and its metabolites were observed in between J774 and HEK-R482 cells, when the efflux profiles of AZT and its metabolites were similar each other. This suggests that AZT-MP is
a major efluxed form of AZT regardless of intracellular metabolic profile in different organ and/or species.

B. Materials and Methods

1. Effect of metabolizing enzymes

HEK-R482 and J774.2 cells were routinely maintained in 75-cm² flasks containing DMEM and MEM media supplemented with 10% fetal calf serum at 37°C / 5% CO₂. Cells were incubated with ³H-AZT (1 µM) and either probenecid or thymidine (20 µM or 1 mM) for 2 hr at 37°C in triplicate in 24-well plates. Following incubation, cells were washed three times with ice-cold PBS buffer, lysed by 1N NaOH (0.2 ml) and analyzed using β-scintillation counting. Quantitation of AZT and AZT phosphates in specific samples was achieved using HPLC analysis described in the next section. Data is presented as mean ± SD. Dunnett’s multiple comparison test after ANOVA is used to compare the statistical differences between groups and statistical significance is determined at the level of $P = 0.05$.

2. Radio-HPLC analysis of AZT and its metabolites

Sample Preparation. For the analysis of AZT and its metabolites in HEK-R482 and J774.2 cells using HPLC method, the cells were washed three times with ice-cold media and frozen immediately in liquid nitrogen. The thawed cells were extracted with 60% methanol, and the extracts were heated at 95°C for 1.5 min. The extracts were centrifuged for clarification at 12,000g for 6 min.
**Chromatography.** AZT and its metabolites was chromatographically separated on a reversed-phase C\textsubscript{18} column (Nova-pak C18, 5 µm, 4.6 mm × 150 mm Waters) with a mobile phase of phosphate buffer (0.2 M) containing tetrabutylammonium hydrogen sulfate (4 mM, pH 7.5) and acetonitrile in the ratio of 97.5:2.5. Flow rate of the mobile phase was 1.5 ml/min with an Agilent 1050 pump. The eluent is monitored for UV absorbance at 270 nm with an Agilent 1050 UV detector and for beta scintillation counting by using the β-RAM detector and the tritium channel. Identification of the radioactive peaks was achieved by comparing retention times and UV chromatograms of metabolites with those of authentic standards. The HPLC conditions described above allowed the separation of AZT from the phosphorylated metabolites and the concomitant determination of the two major hepatic metabolites, AMT and GAZT. On the day of assay, dried tissue extracts were reconstituted with 150-400 µl of water containing cold AZT and AZT-TP. An aliquot was injected onto HPLC system by an Agilent 1050 autosampler. During the process of our analysis, the coefficient of variation of the radioactivity associated with the injected AZT standards was < 7%.

**Quantitation.** Concentrations of AZT-MP and AZT in samples were determined from the slopes of standard curves of the peak area ratio of compound to internal standard versus standard compound concentration. Standard curve slopes were generated by either non-weighted or weighted (1/Y²) least-squares regression analysis.

3.  **Radio-HPLC analysis of ddI and its metabolites**

HPLC analyses were done with a reversed-phase column C\textsubscript{18} column (Novapak C18, 5um, 4.6 mm × 150 mm Waters) and mobile phase A (4% acetonitrile, 25 mM pH 6.0 phosphate
buffer, 5 mM hexyl triethylamine ion-pairing reagent (Regis Technologies)) and mobile phase B (60% acetonitrile, 25 mM phosphate [pH 6.0], 2 mM hexyl triethylamine ion-pairing reagent). The following gradient was used: (1) 5 min of an isocratic flow with 100% mobile phase A at 1.2 ml/min, (2) 35 min of a linear gradient from 0 to 42% mobile phase B at 1.2 ml/min, (3) column washing for 2 min with 100% mobile phase B at 2 ml/min, and (4) 8 min of reequilibration with 100% mobile phase A at 1.2 ml/min. The final eluent was monitored for UV absorbance at 270 nm with an Agilent 1050 UV detector and for beta scintillation counting by the β-RAM detector using the tritium channel. All other details were identical to that described in Method #2.

C. Results

1. Metabolism limits the uptake of AZT and ddI in human embryonic kidney cells and murine macrophage cells

Influence of ATP depletion

The cellular accumulation of AZT and the time profiles for AZT efflux were shown for HEK-R482 (Figure 23) and J774.2 (Figure 24) cells. The efflux profiles follow two elimination phase kinetics in HEK-R482 and J774.2 cells (k1 = 0.078, 0.092, 0.082 min⁻¹, k2 = 0.067, 0.080, 0.070 min⁻¹ for control, ATP regeneration, and ATP depletion in HEK-R482; k1 = 0.55, 0.44, 0.46 min⁻¹, k2 = 0.044, 0.040, 0.037 min⁻¹ in J774.2 cells)
Figure 23. Effect of ATP depletion on (A) cellular uptake and (B) relative efflux of AZT in HEK-R482 cells. ATP depleted cells were maintained in the presence of ATP synthesis inhibitors during the uptake phase. For efflux, cells were either incubated in a substrate-free medium without ATP inhibitors (ATP regen.) or in the continuing presence of the ATP inhibitors (ATP deplet.) (*: p < 0.05, n = 3)
AZT efflux was studied in ATP depleted cells, loaded with AZT in ATP depleting conditions, and transferred to a drug-free medium in ATP depleting conditions. Cells were preincubated for 20 min with NaN$_3$ and 2-D-deoxyglucose to deplete them of ATP. They were then challenged with 1 µM AZT and ddI for 90 min in ATP depleting condition. ATP depletion was originally designed to ablate the efflux of AZT mediated by ABC transporters such as BCRP, but ATP depletion did not cause an increase but rather a marked decrease of AZT uptake in both HEK-R482 and J774.2 cells (Figure 23, Figure 24). AZT is phosphorylated to the monophosphate (AZT-MP) by thymidine kinase, and further phosphorylated to diphosphate (AZT-DP) and triphosphate (AZT-TP) by
thymidylate kinase and deoxynucleoside diphosphate kinase, respectively. ATP depletion can block the oxidative phosphorylation of AZT since the source of the phosphate group is ATP. Inhibition of AZT phosphorylation led to decreased formation of AZT-MP, which is a substrate of MRP4 (Schuetz et al., 1999). The mixed function of ATP supports the efflux data in Figure 23B and Figure 24B showing that the relative efflux rate of AZT in ATP depleting and regenerating conditions was not different compared to the observation in the control group (no ATP depletion). The effect of ATP depletion on the efflux transporters can be segregated from the metabolism by separately measuring the parent AZT and metabolites. Cellular uptake of ddI was also compared among control, ATP regeneration, and ATP depletion conditions. The effect of ATP depletion was minimal in both HEK-R482 cells (control vs. ATP regeneration vs. ATP depletion; 1.36 vs. 1.71 vs. 1.60 pmol/ well) and J774.2 cells (control vs. ATP regeneration vs. ATP depletion; 1.17 vs. 0.93 vs. 0.87 pmol/ well).

**Role of thymidine kinase in cellular uptake of AZT**

The effect of ATP depletion on AZT uptake strongly suggests the involvement of phosphorylation (Elwell et al., 1987), glucuronidation (Resetar and Spector, 1989), and/or uptake transporters (Griffiths et al., 1991). Thymidine kinase is the first in line of the successive phosphorylation of AZT to AZT-TP, and this enzyme is inhibited by an excessive amount of thymidine (Hoggard et al., 1995). Probenecid is known to be an inhibitor of both organic anion transporters (Somogyi, 1996) and glucuronidation (Hauser et al., 1988). The influence of thymidine kinase inhibitors and probenecid on the intracellular uptake of AZT in HEK-R482 and J774.2 cells is compared (Figure 25). It has
been reported that AZT was metabolized predominantly to AZT-MP (approximately 75% of total phosphates) with less AZT-DP and AZT-TP formed (Hoggard et al., 1995).

![Figure 25. Effect of thymidine and probenecid on 3H-AZT accumulation. Cellular accumulation of 3H-AZT (1 uM) in (A) HEK-R482 cells and (B) J774.2 cells after 90 min incubation with/without 20 uM thymidine or 1 mM probenecid (*: p < 0.05, n = 3)](image)

The addition of thymidine (20 µM) resulted in a marked reduction in AZT accumulation in HEK-R482 cells compared to controls whereas the addition of probenecid (1 mM) increased AZT uptake in both HEK-R482 and J774.2 cells. Reduced uptake of AZT by thymidine suggests that ATP depletion is caused by the inhibition of thymidine kinase.

2. Effect of AZT phosphorylation on AZT efflux

To investigate MRPs’ role in the transport of AZT and its metabolites, we examined the uptake and efflux processes in J774 (Figure 26, Figure 27) and HEK-R482 (Figure 28, Figure 29) cells. A typical radiochromatogram had two radioactive peaks. Peaks were characterized by using HPLC cochromatography with authentic cold standards such as AZT and AZT-MP (Figure 30). MK-571 abolished the efflux of AZT-MP in J774 cells
whereas it had no effect on AZT efflux. A similar pattern was observed in HEK-R482 cells suggesting that AZT-MP is a substrate of MRPs.

Figure 26. Effect of MK-571 on 3H-AZT and its metabolites uptake. Cellular uptake of 3H-AZT (1 μM) and its metabolites into J774.2 cells after 30 min incubation with/without 100 μM MK-571 (*: p < 0.05, n = 3)
Figure 27. Effect of MK-571 on the efflux kinetics of 3H-AZT and AZT-MP in J774.2 cells.

J774.2 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (*: p < 0.05, n = 3)
Figure 28. Effect of MK-571 on 3H-AZT and its metabolites uptake. Cellular uptake of 3H-AZT (1 uM) and its metabolites into HEK-R482 cells after 30 min incubation with/without 100 uM MK-571 (*: p < 0.05, n = 3)
Figure 29. Effect of MK-571 on the efflux kinetics of 3H-AZT and AZT-MP in HEK-R482 cells.
HEK-R482 cells were incubated in a drug-free medium with/without MK-571 (100 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without MK-571 (*: p < 0.05, n = 3)
3. 

Effect of ddI phosphorylation on ddI efflux

The effect of MK-571 on the cellular deposition of ddI-originated molecular species in HEK-R482 cells was shown in Figure 31. A typical radiochromatogram, presented in Figure 32 showed only one radioactive peak. The peak was characterized as ddA-TP by using HPLC cochromatography with an authentic cold standard. The major effluxed form of ddI was also examined using radio-HPLC, and it was identified as ddI itself (data not shown). The peak size of ddI was slightly over the detection limit, and it was difficult to claim that ddI was the only effluxed form found in the media.
Figure 31. Effect of MK-571 on 3H-ddI and its metabolites uptake. Cellular uptake of 3H-ddI (1 uM) and its metabolites into HEK-R482 cells after 30 min incubation with/without 100 uM MK-571 (*: p < 0.05, n = 3)
Figure 32. Typical HPLC radiochromatogram of an uptake media sample incubated with 3H-ddI in HEK-R482 cells

D. Discussion

Literature reports have suggested that the tissue-to-plasma ratio (T/P ratio) of AZT was high in the kidney due to the involvement of uptake transporters. Detection of extracellular AZT-MP indicated that AZT-MP was transported outward by an efflux transporter. Sampath et al. reported that AZT-MP is a substrate of MRP4 (Sampath et al., 2002). The low ratios of AZT-MP to AZT in tissue and of AZT-TP to AZT in the mouse kidney (9.6% and 0.1%) indicate that the major intracellular AZT form is AZT itself (Chow et al., 1997; Chow et al., 1998). The current uptake studies of AZT indicated rapid phosphorylation in cultured cells such as human embryonic kidney (HEK-R482) and mouse macrophage (J774.2) cells. Incubation of AZT resulted in the formation of AZT-MP in J774.1 and most of the AZT was effluxed as a parent AZT or AZT-MP. Different patterns of AZT metabolism were monitored depending on the applied cell systems. In HEK-R482 cells, AZT-TP was the predominant metabolite instead of AZT-MP indicating more rapid serial phosphorylation of AZT than in murine J774.1 cells. In the case of ddI, the metabolic
pathway is more complicated than for AZT. ddI-MP was aminated by the adenylsuccinate synthase and lyase enzymes to ddA-MP, which was phosphorylated to the ddA-DP and ddA-TP forms. In the cultured cells, ddI showed lower intracellular level than AZT, probably because ddI has lower permeability to the cell membrane as compared to AZT. The predominant metabolite found in human HEK-R482 was the triphosphate form of ddA (ddA-TP) similar to AZT.

ATP depletion was originally designed to ablate the efflux of AZT mediated by ABC transporters such as BCRP, but ATP depletion did not cause an increase but rather a marked decrease of AZT uptake in both HEK-R482 and J774.2 cells. AZT is phosphorylated to the monophosphate (AZT-MP) by thymidine kinase, and further phosphorylated to diphosphate (AZT-DP) and triphosphate (AZT-TP) by thymidylate kinase and deoxynucleoside diphosphate kinase, respectively. ATP depletion blocks the oxidative phosphorylation of AZT since the source of the phosphate group is ATP. Inhibition of AZT phosphorylation led to decreased formation of AZT-MP, which is a substrate of MRP4 (Schuetz et al., 1999). The mixed function of ATP supports the efflux data showing that the relative efflux rate of AZT in ATP depleting and regenerating conditions was not different compared to the observation in the control group (no ATP depletion). Cellular uptake of ddI was also compared among control, ATP regeneration, and ATP depletion conditions. The effect of ATP depletion was minimal in both HEK-R482 cells and J774.2 cells.

The experiments presented here show that metabolism is closely related to the efflux of AZT and ddI, and the deposited forms of these drugs are sometimes different compared with effluxed form.
V. THE ROLE OF DRUG EFFLUX AND METABOLISM ON THE URINARY DISPOSITION OF AZT AND DDI

A. Introduction

For most drugs, the major routes of drug disposition are hepatic extraction and renal excretion. While hepatic extraction of drugs is mediated by biotransformation and biliary excretion, renal excretion of drugs encompasses glomerular filtration, tubular secretion, tubular reabsorption, intracellular storage, and metabolism. Although glomerular filtration and tubular reabsorption are responsible for the renal clearance of drugs in a number of cases, other mechanisms, such as tubular secretion, intracellular storage, or metabolism of drugs, may also be involved in the renal clearance of drugs. Since the renal clearance of AZT (7.4 ml/min/kg) and ddI (15.7 ml/min/kg) exceeded the normal glomerular filtration rate of rats (5.2 ml/min/kg) it suggests a significant role of tubular secretion in the elimination of these drugs (Doshi et al., 1989). Unlike glomerular filtration, tubular reabsorption and secretion are saturable processes, as transporters mediate vectorial transepithelial transport of drugs. Besides the well-known ability of absorptive transporters to recycle nutrients back to the body (Le Hir and Dubach, 1985; Franco et al., 1990; Gutierrez and Giacomini, 1993), secretory transporters mediate the export of drugs via the basolateral and apical membrane of renal proximal tubular cells into urine thus playing a critical role in drug elimination.

The identification and characterization of organic ion transporters at the basolateral membranes of the kidney are now better understood (Inui et al., 2000). In addition to these organic ion transporters, the ATP-binding cassette (ABC) transporter family located at the
apical membrane such as P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), and breast cancer resistance protein (BCRP) have been suggested as efflux transporters in the kidney (Siegmund et al., 2002; Dietrich et al., 2003; Ito et al., 2005; Cascorbi, 2006). In previous two chapters, it was shown that MRPs and BCRP are responsible for the efflux of AZT and ddI in species specific way and phosphorylation plays a great role in the metabolism of AZT and ddI. Also, the metabolism and efflux of both drugs appear to be closely related to each other. Phosphorylation and transport work as tandem processes in the disposition of AZT and ddI, which introduces an extra complexity to the interpretation of their efflux kinetics. The excretion of AZT and ddI from systemic blood, through renal tubular epithelial cells, and into urine can be considered a three-step process. The first step involves the filtration of AZT and ddI from blood through glomerulus, a passive filtration process dependent only upon size and charge. The second step is reabsorption into renal tubular epithelial cells. Entry of drugs from urine into tubular cells can be achieved via a variety of apical carrier systems. Alternatively, uptake of drugs from systemic blood into tubular cell is achieved through the basolateral membrane. Once inside the tubular cells, the third step of urinary clearance involves transferring drugs back to the microtubular space through the tubular apical membrane. This step of urinary clearance at the tubular apical membrane involves unchanged drug and/or metabolites. Many transporting proteins have been shown to be present on the tubular apical membrane to mediate this process (Thiebaut et al., 1987; Schaub et al., 1997; Schaub et al., 1999; van Aubel et al., 2002). Renal clearance of AZT and ddI including their metabolites accounts for half of the total clearance in our results with mice and in the literature (Doshi et al., 1989; Ahmed et al., 1991). The main scope of
this investigation is to determine whether MK-571 altered the urinary excretion of AZT, ddI, and their metabolites. To elucidate the effect of MK-571 on urinary excretion of AZT and ddI in mice, we collected urine for up to 24 hrs after intravenous injection of AZT and ddI.

B. Materials and Methods

1. Urinary excretion of AZT and ddI in mice

AZT was mixed with $^3$H-AZT in water and this aqueous mixture was used as AZT dosing solution in mice studies. Same procedures were applied to ddI dosing solution. AZT and ddI dosing solutions were intravenously administered at a dose of 10 mg/kg into FVB mice through the tail vein, and administered mice were kept in a metabolic cage (Nalgene, Rochester, NY). During the time of 0 ~ 12 hr and 12 ~ 24 hr, urine samples were collected, the metabolic cage was washed with water, and washing solution was also collected. For specific assay of $^3$H-AZT or $^3$H-ddI itself and metabolites in urine samples, radio-HPLC analysis was applied. A 10x diluted urine sample was vortex mixed in a 1.5-ml polypropylene tube for approximately 10 sec, centrifuged for 20 min at 15,800 g to achieve a clear supernatant, and 100 µL of the supernatant was injected directly onto a radio-HPLC system. $^3$H-AZT and $^3$H-ddI were analyzed using a reverse-phase HPLC on a Nova-Pak C8 column (150×4.6 mm, 5-µm particle size, Waters) fitted with a Nova-Pak C8 Guard-Pak precolumn (Waters). The HPLC system consisted of an Agilent Chemstation control software, Agilent 1050 pumps, Agilent 1050 autoinjector, and IN/US β-RAM radioactivity detector.
2. **Measurement of intrinsic clearance**

FVB mice were euthanized by CO$_2$ inhalation, and the kidneys were immediately placed into freshly oxygenated ice-cold saline. Tissue slices ($\leq$ 0.5 mm; 5~10 mg wet weight) were cut with a Stadie-Riggs microtome and maintained in ice-cold modified Cross and Taggart saline (in mM: 95 NaCl, 80 mannitol, 5 KCl, 0.74 CaCl$_2$, and 9.5 Na$_2$PO$_4$, pH 7.4). Slices were incubated for 1 hr with AZT or ddI with/without inhibitors (10 µM Fumitremorgin C or 50 µM MK-571). After incubation, the slices were removed from the uptake medium, blotted, and weighed. Slices were dissolved in scintillation cocktail and analyzed by liquid scintillation counting method. For radio-HPLC analysis, samples were deproteinized with methanol instead of dissolution with scintillation cocktail. Data were presented as the tissue to medium (T/M) ratios (*i.e.*, dpm/mg tissue divided by dpm/µl medium).

3. **Pharmacokinetic analysis**

The peak plasma concentration ($C_{\text{max}}$) and time to reach a $C_{\text{max}}$ ($T_{\text{max}}$) are read directly from the plasma concentration-time data. The $V_{\text{max}}$ (the maximum velocity) and $K_m$ (Michaelis-Menten constant; the concentration at which the rate is one-half of $V_{\text{max}}$) for the disappearance of AZT and ddI are determined after incubating the liver and kidney slices and drugs. The kinetic constants ($K_m$ and $V_{\text{max}}$) for the disappearance of AZT and ddI are calculated using the Lineweaver-Burk plot with the method of least squares. Data is presented as mean ± SD. Dunnett’s multiple comparison test after ANOVA is used to compare the statistical significance of differences between experimental groups and statistical significance is determined at the level of $P=0.05$. 
C. Results

1. Effect of novobiocin on oral absorption of ddI in rats

An LC-MS/MS assay for the determination of ddI was developed for use with the heparin anticoagulated rat plasma matrix. Mass spectra for ddI are shown in Figure 33 and two strong molecular ions were observed at m/z 495 and 295. ddI is coupled with sodium atom producing the adducts of [M+Na]+ (m/z 495) and [2M+Na]+ (m/z 259).

Figure 33. Mass spectra of ddI at the full scan mode (m/z range = 150 ~ 600).
Detection of ddI was achieved by ESI MS/MS in the positive ion mode using two channels: 495/259 and 259/159 for ddI, 445/234 and 423/212 for ddC (Figure 34).

Figure 34. Chromatogram of ddI and internal standard ddC from the standard sample (2 ug/ml). Multiple reaction monitoring (MRM) mode at four channels: m/z of parent/daughter ion = 495/259 and 259/159 for ddI, 445/234 and 423/212 for ddC, in control serum when methanol was used for deproteinization.

The calibration curve was linear in two phases of 10 ~ 80 ng/ml and 80 ~ 2,000 ng/ml. The usefulness of this LC-MS/MS method to monitor plasma concentrations of ddI was demonstrated in subsequent rat pharmacokinetic results. The plasma concentration–time profile of ddI is shown in the absence and presence of NOV, a known BCRP inhibitor.
The group with NOV showed higher ddI concentrations than in the control group even though the difference was not statistically significant ($p > 0.05$).

**Figure 35.** Mean arterial plasma concentration-time profile of didanosine (ddI) after oral administration at a dose of 20 mg/kg in Sprague-Dawley rats. ddI was administered with/without 50 mg/kg novobiocin (NOV). Each points represents means +/- SD ($n = 3$)

*In vitro* uptake of ddI suggested that ddI was not a substrate for mouse bcrp1 (Figure 13). It is unclear if the NOV effect is mediated by bcrp1 or by other factors.

2. **Intrinsic clearance from mouse kidney slices**

We have observed the efflux processes of AZT and the effect of FTC and MK-571 in mouse kidney slices have been examined in Figure 36 and Figure 37, respectively. The
efflux of AZT and GAZT during the first 60 min in mouse kidney slices was not changed in the presence of FTC (Figure 36). The efflux of GAZT was delayed in mouse kidney slices incubated with MK-571, while the efflux of AZT was same as control (Figure 37). The relative efflux rates of AZT and GAZT was different: the same efflux rate of AZT and GAZT regardless of the presence of MK-571.

Figure 36. Effect of Fumitremorgin C (FTC) on the efflux kinetics of 3H-AZT and GAZT in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without FTC (10 uM) for 60 min after 90 min coincubation of 3H-AZT (1 uM) with/without FTC (*: p < 0.05, n = 3)
Figure 37. Effect of MK-571 on (A) the efflux profile and (B) the relative efflux profile of 3H-AZT and GAZT in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without MK-571 (100 μM) for 60 min after 90 min coincubation of 3H-AZT (1 μM) with/without MK-571 (*: p < 0.05, n = 3)

We have also observed the efflux of ddI and the effect of FTC and MK-571 in mouse kidney slices have been examined in Figure 38 and Figure 39, respectively. The efflux of ddI and ddA-MP during the first 60 min in mouse kidney slices did not change in the presence of FTC (Figure 38). The efflux of ddA-MP was the same as the control, while the efflux of ddI itself was delayed in mouse kidney slices incubated with MK-571 (Figure 39). The relative efflux rates of ddI and ddA-MP with MK-571 was opposite: the same efflux rate of ddI vs. increased efflux rate of ddA-MP.
Figure 38. Effect of Fumitremorgin C (FTC) on the efflux kinetics of 3H-ddl and ddA-MP in mouse kidney slices. Mouse kidney slices were incubated in a drug-free medium with/without FTC (10 uM) for 60 min after 90 min coincubation of 3H-ddl (1 uM) with/without FTC (*: p < 0.05, n = 3)
3. Urinary excretion of AZT and ddi in mice

AZT appeared in the urine and constituted almost all of urinary excreta for 24 hr after intravenous administration of AZT (Figure 40). 32% and 29% of the AZT dose was delivered into urine as AZT throughout the experiment in the absence/presence of MK-571 administered orally at 30 min prior to AZT dosing (50 mg/kg), respectively. The average excreted amount of GAZT was much lower, as it was found only occasionally in the urine. Injected ddi was also excreted into the urine and, in fact it was one of the main forms of urinary excreted ddi (Figure 41). ddi that appeared in the urine accounted for 38% of the total excreted ddi, and the remaining was excreted as the ddi monophosphate form (ddA-MP). The existence of ddA-MP was confirmed by comparing the retention time of the metabolite peak in urine sample with that of cold authentic ddA-MP. 21% and 35% of
the ddI dose was delivered into urine as ddI and ddA-MP in the absence of MK-571, while 17% and 28% of the ddI dose was delivered as ddI and ddA-MP in the presence of MK-571.

Figure 40. Effects of MK-571 on the urinary excretion of AZT in mice. AZT (10 mg/kg) with trace amount of 3H-AZT was injected through the tail vein with or without MK-571 (50 mg/kg). The excreted amount of AZT and GAZT over a period of 24 hr in a urine sample to the percent of the injected amount were determined (p < 0.05, n = 3)
Figure 41. Effects of MK-571 on the urinary excretion of ddl in mice. ddl (10 mg/kg) with
trace amount of 3H-ddl was injected through the tail vein with or without MK-571 (50 mg/kg).
The excreted amount of ddl and ddAT-MP over a period of 24 hr in a urine sample to the
percent of the injected amount were determined (p < 0.05, n = 3)

The inhibitory effect of MK-571 on the urinary excretion of AZT and ddl in mice was
examined. The excreted amount of AZT and ddl was not altered by coadministration of
MK-571, and thus the urinary clearance values of AZT and ddl in the presence of MK-571
were not affected by MK-571 coadministration.

D. Discussion

In a preliminary study, the systemic exposure of ddl after oral dosing to rats was slightly
higher when treated with NOV, a known BCRP inhibitor (Figure 35). However, the in
vitro ddI uptake study in cultured cells and kidney slices suggested that ddI was not a substrate of mouse bcrp1 (Figure 13, Figure 38). MK-571 was used in the mouse in vivo model as a putative transporter inhibitor to determine if efflux was caused by the MRPs instead of bcrp1. Urinary excretion of AZT and ddI were monitored in mice treated with/without MK-571. As a corresponding in vitro model, the metabolism and efflux of AZT and ddI in mouse kidney slices were also investigated. Incubation of AZT in mouse kidney slices resulted in the formation of GAZT with one unknown metabolite in contrast to the results from mouse J774.1. The reason for the unexpected difference of major intracellular metabolites between cultured cells and mouse kidney slices is uncertain. One possible reason for this phenomenon is the variable expression of glucuronidating enzymes, UDP-glucuronosyltransferases. This is supported by the fact that trimethylcyclohexanol was converted to its glucuronide in J774 cells at much slower rate than in rat hepatocytes (White et al., 1990). Contrary to our expectation, no change in AZT or ddI urinary excretion was observed between the MK-571 treated and untreated groups. It is probably because the binding affinity of AZT or ddI to MRPs was not strong enough to show an in vivo effect. Generally, significant in vivo pharmacokinetic changes by efflux transporters are observed only when in vitro inhibition is quite strong. In these experiments, we demonstrate a discrepancy between in vitro and in vivo inhibition of efflux transporters.

VI. DEVELOPMENT OF A NOVEL STRATEGY FOR THE PENETRATION OF NRTIS TO HIV RESERVOIR SITES

A. Introduction
Among the available antiviral drugs approved for the treatment of HIV-1 infected patients, AZT and ddI are still among the most effective drugs. AZT is a drug of choice for the prevention and management of AIDS dementia complex (ADC), because it is the best understood and certainly has better CNS penetration than other drugs such as nucleotide analog reverse transcriptase inhibitors and protease inhibitors. Patients receiving AZT show a general improvement in cognitive functions including attention, memory, motor function, and general cognitive ability (Sidtis et al., 1993). The success of AZT treatment has been attributed to its effective penetration into the brain and spinal fluid unlike recently developed nucleotide analogs such as adefovir. The transport of AZT across blood-brain barrier has been estimated from determinations of AZT levels in the brain tissue of mice. Larger doses (1,000 mg compared to the standard 600 mg/day) of AZT appear to be necessary for the treatment of ADC. However, continued use of AZT has been prohibited in a significant portion of patient population, because of dose-related hematologic toxicity. On the contrary, ddI has not been extensively studied for the treatment of cognitive impairment. Several small studies from clinicians suggest that ddI is less effective than AZT for treating AIDS dementia (Yarchoan et al., 1990). It seems that ddI does not cross the blood-brain barrier well as AZT does. It is estimated that only about 20% of ddI crosses the blood-brain barrier. However, ddI should be considered for people who are not be able to tolerate high doses of AZT.

In addition to brain, lymphocytes are also considered important target cells in HIV-1 treatment, since they are closely related to infectivity and propagation of HIV-1 (Gartner et al., 1986; Ho et al., 1986). To function as reverse transcriptase inhibitors, most NRTIs including AZT and ddI must first be phosphorylated to the triphosphate forms by
intracellular kinases. Unfortunately, the activity level of these enzymes depends on the cell activation state and on the cell type. Resting cells usually have low level of the enzymes responsible for the phosphorylation of nucleoside analogue, whereas activation causes increased activity levels (Gao et al., 1993; Gao et al., 1994).

In the brain and lymphocytes it is now understood that efflux transporters, such as P-glycoprotein, play a significant role in the secretory efflux of drugs from these sanctuary sites thereby attenuating the penetration of drug into brain and lymphocytes (Gupta and Gollapudi, 1993; Schinkel, 1999). Efflux transporters are saturable, inducible, inhibitable and display some degree of polymorphism. All of this needs to be considered with respect to variability in drug disposition and response (Liu and Hu, 2000).

Recent studies demonstrated that some of multidrug resistance related proteins (MRPs) are involved in pumping anionic substances out against a concentration gradient (Borst et al., 2000), which can be overcome by MRP inhibitors such as MK-571. MRPs are present in various organs: MRP1 and MRP5 are expressed in kidney, MRP2 and MRP3 are highly expressed in liver, only MRP5 is expressed in brain in substantial amount, and MRP4 is expressed at very low levels in a few tissues (Kool et al., 1997). Experiments performed on the mouse macrophage cells (J774), and human embryonic kidney cells (HEK) in previous chapters suggested that AZT and ddI are substrates of MRPs. Currently, two of the MRP family, MRP4 and MRP5, are known to be capable of transporting NRTIs such as adefovir as well as AZT-MP (Schuetz et al., 1999; Lee et al., 2000; Chen et al., 2001).

For successful therapy of AIDS patients using NRTIs, improvement of pharmacological and pharmacokinetic properties of NRTIs is required. Since intracellular phosphorylation is a key event for the anti-HIV effect of AZT and ddI, it is important to investigate if the
increased intracellular concentration of AZT or ddI generates an increased anti-HIV effect. Our preliminary results suggest that suppression of drug efflux transporters can increase the exposure of viral reservoirs to AZT and ddI. If boosting can be applied to the clinical situation, effective treatment of AIDS, especially AIDS dementia, will be possible. However, there are few cases of significant in vivo inhibition of efflux transporters suggesting that in vivo inhibition may not occur even though transporter inhibition may occur at the cellular level. Thus, it is important to verify if the in vitro inhibition of efflux transporters leads to pharmacokinetic boosting in an animal model.

B. Materials and Methods

1. In vivo silencing of efflux transporters

Predesigned siRNAs (siBCRP) were purchased from Dharmacon. In mouse studies, male Balb/c or FVB mice, age 4 ~ 8 weeks, weighing 15 ~ 40 g, were purchased from Taconic (Hudson, NY). Anesthesia was induced with ketamine/xylazine (80/10 mg/kg, ip injection). The mice were dosed intravenously via a fast tail vein injection over 7-10 seconds with the siRNA dissolved in Ringers’ solution. The total injection volume per mouse (in ml) was calculated by dividing the weight of the mouse (in g) by 10. In siRNA distribution studies, mice have free access to food and water. One or more days after intravenous administration of siRNA, mice were euthanized by CO₂ inhalation. Selected tissues, such as the liver, intestine, brain, lung, and kidney were collected to measure the transporter expression in each tissue by Western blot or RT-PCR. Each organ were stored in 1.5 ml tube and frozen in liquid nitrogen right after taken from the body. They were
stored in a freezer at -80°C until further analysis. Each set were tested in 3 mice to achieve adequate statistic power.

2. *In situ brain perfusion*

Male FVB mice (20 ~ 30g, 5 ~ 8 weeks old, Taconic) were used in *in situ* brain perfusion experiments. Mice were maintained under standard conditions with *ad libitum* access to food and water. Mice were anesthetized with ketamine/xylazine (140/8 mg/kg, ip injection). The common carotid artery was exposed and ligated caudally, then the external carotid artery was ligated at the bifurcation of the common carotid artery with the internal carotid artery as shown in Figure 42.

![Figure 42. Structure of the carotid arteries around the neck of FVB mouse.](image)
The left common carotid artery was catheterized with the polyethylene tubing (0.28-mm ID X 0.65-mm OD, A-M systems, WA) filled with heparin (25 U/mL). Immediately before perfusion, the heart beat was stopped by cutting the cardiac ventricles. Brains were perfused for various times at 37 °C using an infusion pump (Harvard, MA). The perfusate contains target compound in Krebs/bicarbonate buffer containing D-glucose, gassed with 95% O₂/5% CO₂ for pH control (7.4).
### Components Concentration (mM)

<table>
<thead>
<tr>
<th>Components</th>
<th>Concentration (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaCl</td>
<td>128</td>
</tr>
<tr>
<td>KCl</td>
<td>4.2</td>
</tr>
<tr>
<td>NaHCO_3</td>
<td>24</td>
</tr>
<tr>
<td>NaH_2PO_4</td>
<td>2.4</td>
</tr>
<tr>
<td>CaCl_2</td>
<td>1.5</td>
</tr>
<tr>
<td>MgSO_4</td>
<td>0.9</td>
</tr>
<tr>
<td>Distilled water</td>
<td>Remaining</td>
</tr>
</tbody>
</table>

In the case of measuring the brain vascular volume, $^3$H inulin was used instead of the target compound as a vascular volume marker. The perfusion was terminated by decapitating the mouse. The brain was removed from the skull and cleaned with paper tissue, then stored in -80°C until analysis. Right and left hemispheres must be separated immediately and so does the removal of Cerebellum. All data were reported for the perfused hemisphere.

Brain vascular volume ($V_{\text{vasc}}$, ml·100 g$^{-1}$), the ratio of the vascular marker concentration in brain to that in perfusate, was determined using the following equation: $V_{\text{vasc}}=X^*/C^*$, where $X^*$ was the amount of radiolabeled inulin in the brain (dpm · 100 g$^{-1}$) and $C^*$ was the perfusate concentration. Initial brain uptake clearances ($Cl_{\text{up}}$, ml · 100 g$^{-1}$ · min$^{-1}$) was the following relationship: $Cl_{\text{up}}=dX_{\text{brain}}/dt/C_{\text{pf}}$, where $X_{\text{brain}}$ was the amount of target compound in the brain corrected for vascular contamination ($X_{\text{total}}-V_{\text{vasc}} \cdot C_{\text{pf}}$) and $C_{\text{pf}}$ was the tracer concentration in the perfusate. In single time point experiment, $X_{\text{brain}}/T$ replaced $dX_{\text{brain}}/dt$, where $T$ was the perfusion time (min). Apparent brain distributional volumes
(V_{\text{brain}}, \text{ ml} \cdot 100 \text{ g}^{-1}) \text{ were calculated from } V_{\text{brain}}=X_{\text{brain}}/C_{\text{pf}}. \text{ In order to obtain the } PA \text{ product, the Crone Renkin model of capillary transport was used: } PA \text{ was defined as } F \ln(1-K_{\text{in}}/F), \text{ where } F \text{ was the regional cerebral perfusion fluid flow, which was determined using } ^{14}\text{C diazepam in separate experiments; } K_{\text{in}} \text{ was the unidirectional transfer coefficient from blood to brain which can be estimated in the same way of } Cl_{\text{up}}; P \text{ was the apparent permeability coefficient of the BBB for a test compound; and } A \text{ was the mouse brain capillary surface area. } P \text{ can be calculated by dividing } PA \text{ by } A. \text{ Data was presented as mean ± SD. Dunnett’s multiple comparison test after ANOVA was used to compare the statistical significance of differences between experimental groups and statistical significance was determined at the level of } P=0.05.

C. Results

1. In vivo silencing of efflux transporters

Hydrodynamic injection of siBCRP was developed for the knock-down of mouse bcrp1, and the expression level of bcrp1 was measured for the control and siBCRP group (Figure 43). Expression of bcrp1 in the liver of the siBCRP treated mouse was significantly lower than in the control group (*: p < 0.05). Expression levels of mouse bcrp1 in the kidney showed no changes, consistent with published studies (Giladi et al., 2003; Lewis and Wolff, 2005). This knock-down system can be utilized to monitor the effect of bcrp1 on disposition, especially hepatic excretion of AZT and ddI.
Figure 43. Effect of in vivo injection of naked siRNA of bcrp1. One day after IV injection (50 ug siRNA), protein was extracted respectively from liver and kidney and Western blot were performed. Each points represents means+SD (*: p < 0.05, n = 3)

2. **In situ brain perfusion**

The brain uptake properties of ddI in the presence of MK-571, a specific MRPs inhibitor were characterized using the brain perfusion technique to investigate the *in vivo* contribution of MRPs on brain uptake of ddI (Figure 44). The addition of MK-571 (100 µM) in the perfusates did not increased the $V_{\text{brain}}$ values of ddI compared with ddI alone. As a positive control for MRPs inhibition by MK-571, inhibition of SQV brain uptake was examined (Figure 45). The $V_{\text{brain}}$ values of ddI in the absence of MK-571 were constant over the range of 10 nM to 10 µM (Figure 46). The selected concentration range covered the plasma concentrations of ddI at clinically recommended dose; $C_{\text{max}}$ of ddI equals 5.5 ± 2.3 µM at 200 mg b.i.d. dose (Sahai et al., 1995). Concentration independent brain uptake confirmed that no influx or efflux transporters were involved in brain uptake of ddI.
Figure 44. Apparent brain distributional volumes of 3H-ddI (1 uM) in the absence and presence of MK-571 (100 uM), which was included in the perfusates. Brain vascular volume was measured using 14C-sucrose. The mice were perfused for 60 sec and perfusion flow rate was 2.1 ml/min (n = 4)
Figure 45. Apparent brain distributional volumes of 14C-SQV (1 uM) in the absence and presence of MK-571 (100 uM), which was included in the perfusates. Brain vascular volume was measured using 3H-mannitol. The mice were perfused for 60 sec and perfusion flow rate was 2.1 ml/min (n = 4)
Figure 46. Apparent brain distributional volumes of ddI versus concentration of ddI, which was included in the perfusates. Brain vascular volume was measured using 14C-sucrose. The mice were perfused for 60 s. Perfusion flow rate was 2.1 ml/min (*: p < 0.05, n = 4)

D. Discussion

The aim of this chapter was to develop an effective delivery strategy for NRTIs to HIV reservoir sites such as brain by circumventing the efflux mediated by ABC transporters such as BCRP and MRPs. In preliminary work, in vivo hydrodynamic injection of siRNA has been used to silence the mouse bcrp1 gene. This work is critical since high systemic exposure to NRTIs eventually leads to high accumulation of NRTIs in HIV reservoir sites. However, effective knockdown of the mouse bcrp1 gene by siRNA has been achieved only in liver and not in other tissues such as brain and kidney after hydrodynamic injection to mice. Hydrodynamic tail vein injection needs large dosing volumes over a short period.
Although this harsh dosing condition makes it difficult to apply hydrodynamic injection to clinical use, this technique is still promising as an experimental tool to evaluate the *in vivo* role of various uptake and efflux transporters especially in the mouse liver. Unfortunately, literature search suggested that no gene suppression in brain is expected after hydrodynamic injection of siRNA. Thus, effect of efflux transporters in brain uptake of ddI were investigated with chemical inhibitor MK-571 instead of siRNA. Brain uptake expressed as $V_{\text{brain}}$ of ddI was not affected by MK-571, while saquinavir as positive control showed significant increase of brain uptake (Figure 44).

**VII. OVERALL SUMMARY AND CONCLUSIONS**

AZT and ddI are potent NRTIs and the oldest drugs to be approved by FDA for the treatment of HIV infection. These two NRTIs have been prescribed more often than any other antiviral drugs since the FDA approved them. Although AZT and ddI have been studied extensively for more than 20 years, the mechanisms behind their significant differences in absorption and disposition have not been well characterized. The focus of this research was to delineate the contribution of each pharmacokinetic process and metabolizing enzyme or transporters that affect the pharmacokinetics of AZT and ddI, and the specific objectives of this research were to:

1. Identify the contribution of efflux transporters such as BCRP and MRPs on the renal excretion of AZT and ddI.
2. Characterize the diverse metabolic pathways of AZT and ddI in animal and human cells.
3. Evaluate the role of drug efflux and metabolism on the urinary disposition of AZT and ddI.

4. Develop the novel strategy of the penetration of NRTIs to HIV reservoir site.

For the first objective, uptake and efflux studies of 3H-AZT or 3H-ddI with/without transporter inhibitors were performed in human HEK-R482 and mouse J774.1 and J774.2 cells. The renal clearances of two NRTIs are much greater than the Glomerular Filtration Rate (GFR) suggesting active secretion of these two drugs. Although AZT is assimilated into the epithelial kidney cells by organic anion transporters, the tissue distribution of AZT is moderate indicating the presence of AZT efflux transporter. The influx of ddI is also mediated by organic anion transporters, and the distribution in the kidney is only two-fold higher than plasma levels in rats. Interestingly, species differences in substrate specificity to the efflux transporter were observed. Neither bcrp1 nor mrps play a significant role in the efflux of AZT in mice, while both BCRP and MRPs altered the uptake and efflux of AZT significantly in human. The efflux properties of ddI were quite different from those of AZT: the effect of bcrp1 or BCRP on efflux of ddI was minimal; only MRP1 out of the four tested MRP subfamilies (MRP1 ~ 4) was responsible for ddI efflux and only to a marginal extent. Another key finding was that different MRP subfamilies were responsible for efflux of AZT and ddI. The efflux of AZT was greatly modulated by siMRP3 and siMRP4, and efflux of ddI was delayed only by siMRP1 to a moderate degree indicating that the major inhibition effect of MK-571 treatment might be caused by the inhibition of transporters other than MRPs. The identification of the efflux transporters is important for
understanding the elimination profiles of these NRTIs. The information obtained can be used to predict drug-drug interactions between AZT or ddI and other prescribed drugs. Metabolic profiles of 3H-AZT and 3H-ddI were characterized using radio-HPLC. Cellular uptake studies indicated rapid phosphorylation of AZT in HEK-R482 and J774.2 cells. Incubation of AZT resulted in the formation of AZT-MP in J774.1 and most of AZT was effluxed as a form of AZT or AZT-MP. However, AZT-TP was the predominant metabolite indicating faster serial phosphorylation of AZT in HEK-R482 cells than in J774.1 cells. In the case of ddI, the metabolic pathway was more complex than AZT. In cell systems, ddI showed lower intracellular concentrations compared to those of AZT, probably because ddI is less permeable to cell membranes than AZT. The predominant metabolite found in human HEK-R482 was the triphosphate form of ddA (ddA-TP) similar to AZT. ATP depletion and subsequent inhibition of AZT phosphorylation led to decreased formation of AZT-MP, which is a substrate of MRP4. The mixed function of ATP supports the efflux data showing that the relative efflux rate of AZT in ATP depleting and regenerating conditions was not different compared to the observation in the control group (no ATP depletion). Cellular uptake of ddI was also compared among control, ATP regeneration, and ATP depletion conditions. The effect of ATP depletion was minimal in both HEK-R482 cells and J774.2 cells. The experiments presented here show that metabolism is closely related to drug efflux of AZT and ddI, and the deposited forms of these drugs are sometimes different compared to the effluxed form.

Preliminary data indirectly suggested that BCRP was involved in plasma disposition of ddI in rats. But, subsequent in vitro studies did not support that BCRP was a substrate of ddI in cultured cells and kidney slices. The effect of MRP on mouse renal excretion of AZT and
ddI was assessed instead of the BCRP effect in mice *in vitro* and *in vivo* models. Outward transport of AZT was not apparently affected by FTC or by MK-571 in mouse kidney slices suggesting no involvement of efflux transporters in outward transport of AZT itself. However, accumulated efflux of GAZT significantly decreased when treated with MK-571. The overall process of AZT disposition involves the intracellular metabolism of AZT to GAZT and the subsequent pumping GAZT out possibly by MRPs in mouse kidney. Renal excretion of AZT was measured in mice when coadministered with MK-571. Far from *in vitro* results, no change of AZT or ddI urinary excretion was observed between MK-571 treated and untreated group. It is probably because the binding affinity of AZT or ddI to MRPs was not strong enough to show significant *in vivo* effect.

In case of ddI, efflux of ddI itself was decreased when treated with MK-571 and ddA-MP was not significantly changed by addition of MK-571. Urinary excretion of ddI or ddA-MP was not changed when coadministered with MK-571 and the possible cause of this phenomenon is same as the case of AZT. The kidney and liver are two of the major organs involved in drug disposition in gerenal. The renal clearance of AZT and ddI accounts for 30 ~ 50% of total body clearance after intravenous dosing while hepatic clearance is expected to cover the major portion of nonrenal clearance. Urinary excretion profile of AZT and ddI can be an indirect marker of these two drug’s plasma disposition profile. The different renal disposition profile between AZT and ddI could not be explained by efflux transporters and rather the renal metabolism might be a main governing factor in renal disposition of these drugs.
Last objective is related with our long term goal to develop a more effective dosing regimen for NRTIs in treating HIV/AIDS. As long as an appropriate dosing regimen is established, chemical and biological inhibitors of efflux transporters can circumvent the low assimilation into viral reservoirs thus improving pharmacokinetics. Literatures suggest that drug efflux might hamper NRTI therapy in AIDS patients. Preliminary work was focused on the development of mouse model with specific transporter knock-down. The hydrodynamic injection itself was proven to be an effective tool to ablate the expression of target transporter gene and protein, but influence of efflux transporters on AZT and ddI could not be investigated with this technique, because it did not silence transporter in target organ such as brain and kidney. Chemical inhibition using MK-571 was used in in situ brain perfusion study as an alternative inhibition tool. Future study for developing enhanced dosing regimen must be focused more on metabolism than on efflux in these two reservoir sites.

Inhibitors of efflux transporters will be characterized at the cellular level and in animal studies. Effect of these inhibitors on pharmacodynamics of NRTIs using an HIV-infected cell system will be also assessed.

VIII. REFERENCES


IX. CURRICULUM VITAE

Name: Sung-Hack Lee

Position: Head of Drug Metabolism and Pharmacokinetics
LG Life Sciences, Ltd. / R&D
104-1 Munji-dong, Yuseong-gu, Daejeon
305-380, Korea
Phone: 82-42-866-2287
E-mail: shleeap@lgls.com

Professional Activity and License:
Manager, 2006-Present, DMPK Team, LG Life Sciences, Korea
Teaching Assistant, 2003-2006, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Graduate Assistant, 2001-2003, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Research Scientist, 1996-2001, Department of DMPK, LG Life Sciences, Korea
Pharmacist License, 1994, Ministry of Health and Welfare, Korea

Educations:
Ph.D., 2008, Pharmaceutics, Rutgers, The State University of New Jersey (Major Adviser: Patrick J. Sinko, Ph.D.)
M.S., 1996, Pharmaceutics, Seoul National University, Korea (Major Adviser: Chang-Koo Shim, Ph.D.)
B.S., 1994, Manufacturing Pharmacy, Seoul National University, Korea

Scholarships:
- Nam-Chuck Scholarship (3/91-2/94), Full tuition

Research Interests and Techniques:
- Transporter mediated pharmacokinetic boosting of HIV protease inhibitors
- Transporter mediated BBB efflux of anti-cancer and/or anti-HIV drugs
- Differentiation of intestinal and hepatic first pass effect of drugs in rabbit model
- General drug metabolism using hepatic S9 and/or microsomal fraction
- In vivo preclinical pharmacokinetics in the rats, dogs, and monkeys
- Development and validation of bioanalytical method using HPLC and LC/MS-MS

Publications:


**Patent:**
Kyo-Han Ahn, Suk-Jong Lee, Sung-Hack Lee, Jae-Sun Kim, Chang Yong Hong, Tae-Kyo Park, Jung-In Oh, Hee-Dong Park, Hee-Jin Kim, and Chang-Ho Lee N-(4-amino) butyl-3-phenylpyrrolidine derivative, it's synthesis and formulation as an anxiolytic and antidepressant agent, KR0237542 (1999)